

(19) World Intellectual Property Organization  
International Bureau



(43) International Publication Date  
21 June 2001 (21.06.2001)

PCT

(10) International Publication Number  
**WO 01/44282 A2**

- (51) International Patent Classification<sup>7</sup>: **C07K 14/00**
- (21) International Application Number: PCT/US00/33793
- (22) International Filing Date:  
13 December 2000 (13.12.2000)
- (25) Filing Language: English
- (26) Publication Language: English
- (30) Priority Data:  
09/461,641 14 December 1999 (14.12.1999) US
- (63) Related by continuation (CON) or continuation-in-part (CIP) to earlier application:  
US 09/461,641 (CIP)  
Filed on 14 December 1999 (14.12.1999)
- (71) Applicant (for all designated States except US): **THE BURNHAM INSTITUTE** [US/US]; 10901 N. Torrey Pines Road, La Jolla, CA 92037 (US).
- (72) Inventors; and
- (75) Inventors/Applicants (for US only): **REED, John, C.** [US/US]; 17044 El Camino Real, P.O. Box 137, Rancho Santa Fe, CA 92067 (US). **GODZIK, Adam** [PL/US]; 9184 Buckwheat Street, San Diego, CA 92129 (US).
- (74) Agents: **CADENA, Deborah, L.** et al.; Campbell & Flores LLP, 7th floor, 4370 La Jolla Village Drive, San Diego, CA 92122 (US).
- (81) Designated States (*national*): AE, AG, AL, AM, AT, AU, AZ, BA, BB, BG, BR, BY, BZ, CA, CH, CN, CR, CU, CZ, CZ (utility model), DE, DE (utility model), DK, DK (utility model), DM, DZ, EE, EE (utility model), ES, FI, FI (utility model), GB, GD, GE, GH, GM, HR, HU, ID, IL, IN, IS, JP, KE, KG, KP, KR, KZ, LC, LK, LR, LS, LT, LU, LV, MA, MD, MG, MK, MN, MW, MX, MZ, NO, NZ, PL, PT, RO, RU, SD, SE, SG, SI, SK, SK (utility model), SL, TJ, TM, TR, TT, TZ, UA, UG, US, UZ, VN, YU, ZA, ZW.
- (84) Designated States (*regional*): ARIPO patent (GH, GM, KE, LS, MW, MZ, SD, SL, SZ, TZ, UG, ZW), Eurasian patent (AM, AZ, BY, KG, KZ, MD, RU, TJ, TM), European patent (AT, BE, CH, CY, DE, DK, ES, FI, FR, GB, GR, IE, IT, LU, MC, NL, PT, SE, TR), OAPI patent (BF, BJ, CF, CG, CI, CM, GA, GN, GW, ML, MR, NE, SN, TD, TG).
- Published:**  
— Without international search report and to be republished upon receipt of that report.
- For two-letter codes and other abbreviations, refer to the "Guidance Notes on Codes and Abbreviations" appearing at the beginning of each regular issue of the PCT Gazette.



**WO 01/44282 A2**

(54) Title: BCL-G POLYPEPTIDES, ENCODING NUCLEIC ACIDS AND METHODS OF USE

(57) Abstract: The invention provides Bcl-G polypeptides and encoding nucleic acids. Bcl-G polypeptides include Bcl-G<sub>L</sub> and Bcl-G<sub>S</sub>. The invention also provides mouse Bcl-G. The invention also provides vectors containing Bcl-G nucleic acids, host cells containing such vectors, Bcl-G anti-sense nucleic acids and related compositions. The invention additionally provides Bcl-G oligonucleotides that can be used to hybridize to or amplify a Bcl-G nucleic acid. Anti-Bcl-G specific antibodies are also provided. Further provided are kits containing Bcl-G nucleic acids or Bcl-G specific antibodies. Such kits and reagents can be used to diagnose cancer, monitor response to therapy, or predict the prognosis of a cancer patient. The invention additionally provides methods of modulating apoptosis using Bcl-G polypeptides, encoding nucleic acids, or compounds that modulate the activity or expression of Bcl-G polypeptides. The methods for modulating apoptosis can be used to treat diseases such as cancer.

**BCL-G POLYPEPTIDES, ENCODING NUCLEIC ACIDS AND  
METHODS OF USE**

This invention was made with government support under grant number GM60554 awarded by the National  
5 Institutes of Health. The government has certain rights in the invention.

**BACKGROUND OF THE INVENTION**

The present invention relates generally to regulation of programmed cell death and more specifically  
10 to molecules that promote programmed cell death.

In essentially all self-renewing tissues, a balance is struck between cell production by mitogenesis and cell loss due to programmed cell death, thereby maintaining total cell numbers within a physiologically  
15 appropriate range. In pathological conditions, however, the balance in cell production and cell loss can be disrupted. In cancer, for example, an increased amount of cell production due to a shortened cell cycle time or a decreased amount of cell death due to dysregulation of  
20 a programmed cell death pathway results in the growth of a tumor.

With regard to programmed cell death, a variety of stimuli, which occur either external or internal to the cell, initiate a pathway that ultimately results in  
25 apoptosis of the cell. As is common for most signal transduction pathways, the various different stimuli that induce apoptosis likely initiate the process of programmed cell death through specific pathways. However, most if not all of these initial pathways  
30 converge at a common point that generally involves a

member of the Bcl-2 family of proteins.

The Bcl-2 family of proteins regulate a distal step in the evolutionarily conserved pathway for programmed cell death and apoptosis, with some members of this family functioning as suppressors of cell death (anti-apoptotic proteins) and other members functioning as promoters of cell death (pro-apoptotic proteins). Overexpression of the anti-apoptotic protein, Bcl-2, for example, blocks neuronal cell death that otherwise is induced *in vitro* by various stimuli, including neurotrophic factor withdrawal, various oxidants, glucose deprivation, certain neurotrophic viruses, and amyloid  $\beta$ -peptide. In addition, Bcl-2 is overexpressed in some tumor cells and, in part, may contribute to tumor growth by altering the balance between cell division and cell death.

The Bcl-2 family of proteins are critical regulators of pathways involved in apoptosis, acting to either inhibit or promote cell death (Reed, Nature 387:773-776 (1997); Green and Reed, Science 281:1309-1312 (1998); Reed, Oncogene 17:3225-3236 (1998); Reed, Curr. Opin. Oncol. 11:68-75 (1999)). The Bcl-2 family members can be divided into two groups, those with anti-apoptotic activity, including Bcl-2 and Bcl-X<sub>L</sub>, and those with pro-apoptotic activity, including Bax and Bak.

Four distinct domains have been identified in Bcl-2 family members, designated BH1 to BH4. The BH4 domain is a domain that mediates interactions with a variety of cellular proteins (Reed, *supra*, 1998). The BH1, BH2 and BH3 domains form a binding pocket for dimerization with other Bcl-2 members having a BH3 domain, which also functions as a ligand that binds to

the dimerization binding pocket. The dimerization function of the Bcl-2 members is an important mechanism for regulating apoptosis in that heterodimerization of pro-apoptotic Bcl-2 members with anti-apoptotic Bcl-2 members can regulate the cellular apoptotic pathways. Some Bcl-2 members only have a BH3 domain and therefore function as trans-dominant inhibitors of anti-apoptotic proteins such as Bcl-2 and Bcl-X<sub>L</sub> (Reed, *supra*, 1998).

Another function of Bcl-2 members is the formation of ion channels. Bcl-2 members can localize to the mitochondrial membrane, and the formation of ion pores that alter the permeability of mitochondria is thought to be an important signaling mechanism for the induction of apoptosis. Thus, Bcl-2 members use at least three mechanisms to regulate apoptotic activity: dimerization with Bcl-2 members, formation of ion pores in mitochondria, and binding to non-Bcl-2 members that function as signaling molecules.

In comparison, overexpression of the pro-apoptotic protein, Bax, for example, promotes cell death when triggered by a variety of inducers of apoptosis, including growth factor withdrawal, ionizing radiation, and anti-Fas antibody. In addition, elevations in Bax expression occur in association with cell death induced by a variety of stimuli, including neuronal cell death that occurs due to ischemia, epilepsy, spinal cord injury, and certain neurodegenerative diseases such as Parkinson's disease and Alzheimer's disease.

Although aberrant expression of members of the Bcl-2 family of proteins is associated with various pathologic conditions, the mechanisms by which these

proteins mediate their action is not known. Often, the action of a protein can be inferred from its structural relationship to other proteins, whose functions are known. However, while the Bcl-2 family proteins share certain structural homologies with each other, they do not share substantial amino acid sequence homology with other proteins, further hindering attempts to understand how the Bcl-2 family proteins such as Bcl-2 and Bax regulate cell death.

Thus, a need exists to identify proteins involved in the programmed cell death pathway and to identify methods of regulating programmed cell death for therapeutic applications, including treatment of cancer. The present invention satisfies this need and provides related advantages as well.

#### SUMMARY OF THE INVENTION

In accordance with the present invention, there are provided Bcl-G polypeptides and encoding nucleic acid molecules. The invention polypeptides and encoding nucleic acids are useful for modulating apoptosis by altering the expression or activity of Bcl-G. The Bcl-G polypeptides and encoding nucleic acids can be advantageously used to diagnose or treat cancer, in particular prostate, ovarian and leukemia. Furthermore, the Bcl-G polypeptides and encoding nucleic acids are useful to generate or screen for agents that can alter Bcl-G activity or expression, which can further be used to treat cancer. Bcl-G polypeptides include Bcl-G<sub>L</sub> and Bcl-G<sub>S</sub>.

The invention also provides vectors containing Bcl-G nucleic acids, host cells containing such vectors,

Bcl-G anti-sense nucleic acids and related compositions. The invention additionally provides Bcl-G oligonucleotides that can be used to hybridize to or amplify a Bcl-G nucleic acid. Anti-Bcl-G specific antibodies are also provided. Further provided are kits containing Bcl-G nucleic acids or Bcl-G specific antibodies. Such kits and reagents can be used to diagnose cancer, monitor response to therapy, or predict the prognosis of a cancer patient. The invention additionally provides methods of modulating apoptosis using Bcl-G polypeptides, encoding nucleic acids, or compounds that modulate the activity or expression of Bcl-G polypeptides. The methods for modulating apoptosis can be used to treat diseases such as cancer.

#### BRIEF DESCRIPTION OF THE DRAWINGS

Figure 1 shows the nucleotide sequence of human Bcl-G<sub>L</sub> cDNA (SEQ ID NO:1).

Figure 2 shows the nucleotide sequence of the coding region of human Bcl-G<sub>L</sub> cDNA (nucleotide 196-1179 of SEQ ID NO:1) and the encoded amino acid sequence (SEQ ID NO:2). Bcl-G<sub>L</sub> contains a BH3 domain (<sup>216</sup>LKYSQDQLE<sup>224</sup>; SEQ ID NO:5) and a BH2 domain (<sup>307</sup>PWIQQHGGWE<sup>316</sup>; SEQ ID NO:6).

Figure 3 shows the nucleotide sequence of human Bcl-G<sub>S</sub> cDNA (SEQ ID NO:3).

Figure 4 shows the nucleotide sequence of the coding region of human Bcl-G<sub>S</sub> cDNA (nucleotide 196-954 of SEQ ID NO:3) and the encoded amino acid sequence (SEQ ID NO:4). Bcl-G<sub>S</sub> contains only the BH3 domain (<sup>216</sup>LKYSQDQLE<sup>224</sup>; SEQ ID NO:5).

Figure 5 shows sequence analysis of Bcl-G cDNAs. Figure 5A shows the predicted amino acid sequences of the Bcl-G<sub>L</sub> and Bcl-G<sub>S</sub> proteins, with the BH2 and BH3 domains in bold-type and residue numbers indicated. The predicted proteins are identical from residues 1-226. The unique C-terminal region of Bcl-G<sub>S</sub> is indicated in italics type. Figure 5B shows an alignment of the BH2 domains of Bcl-G<sub>L</sub> (SEQ ID NO:9) and several other Bcl-2 family proteins (SEQ ID NOS:10-17, respectively). Identical and similar residues are shown in black and gray blocks, respectively. Figure 5C shows an alignment of the BH3 domains Bcl-G (SEQ ID NO:18) and several other Bcl-2 family proteins (SEQ ID NOS:19-26, respectively). Figure 5D shows the exon-intron organization of the *BCL-G* gene. The *BCL-G* gene contains 6 exons, spanning a ~30 kb region of chromosome 12. Alternative splicing at the 5'-end of exon 5 accounts for the production of the Bcl-G<sub>L</sub> and Bcl-G<sub>S</sub> proteins, where splice-acceptor sites at nucleotide positions 63,870 versus 63,797 in BAC clone RPCI 11-267J23 (GenBank AC007537) are utilized for Bcl-G<sub>L</sub> and Bcl-G<sub>S</sub>, respectively. The positions of the start and termination codons are indicated, with coding regions in gray blocks and non-coding 5'-UTR and 3'-UTR sequence in open blocks. The BH3 domain is located in exon 4 of both Bcl-G<sub>L</sub> and Bcl-G<sub>S</sub>, while the BH2 domain resides in exon 5 of Bcl-G<sub>L</sub>.

Figure 6 shows mapping of Bcl-G to chromosome 12p12.3.

Figure 7 shows expression of Bcl-G<sub>S</sub> and Bcl-G<sub>L</sub> in human tissues. The expression of transcripts encoding Bcl-G<sub>L</sub> or Bcl-G<sub>S</sub> was examined by RT-PCR. First-strand cDNA prepared using RNA samples from various adult human tissues was PCR amplified using primers specific for Bcl-

$G_L$  and Bcl- $G_S$ , based on differences in splice-acceptor utilization in exon 5. The primers flank an intron in both cases, thus excluding amplification due to contaminating genomic DNA. PCR products were size-fractionated in 2% agarose gels, stained with ethidium bromide, then photographed under UV-illumination.

Figure 8 shows the effect of Bcl- $G_S$  on cell death. PC-3 cells were transfected with pcDNA3.1/Myc/His (control), pcDNA3.1/Myc/His/Bcl- $G_S$  (Bcl- $G_S$ ), pcDNA3.1/Myc/His/Bcl- $G_S$  + pRC/CMV/Bcl-2 (Bcl- $G_S$  + Bcl-2), pRC/CMV/Bax (Bax), or pRC/CMV/Bax + pRC/CMV/Bcl-2 (Bax + Bcl-2). Cells were tested for cell death 24 hours after transfection.

Figure 9 shows induction of apoptosis by Bcl- $G$ . Figure 9A shows the results of transfecting plasmids encoding GFP, GFP-Bcl- $G_S$ , or GFP-Bcl- $G_L$  into Cos-7 cells alone or in combination with a plasmid encoding Bcl- $X_L$ . Apoptosis was examined by DAPI staining at 24 h post-transfection (mean + SD; n = 3) (top). Levels of GFP and GFP-Bcl- $G$  fusion proteins were examined by immunoblotting lysates from transfected Cos-7 cells (20  $\mu$ g per lane) and anti-GFP antibody with ECL-based detection (middle). Equal loading was confirmed by reprobing the same membrane with anti-Tubulin antibody (bottom). Figure 9B shows the results of transfecting plasmids encoding GFP, GFP-Bcl- $G_S$  or the mutant proteins, Bcl- $G_S$  ( $\Delta$ BH3) and GFP-Bcl- $G_S$  (L216E) into Cos-7 cells. The percentage of apoptotic cells was examined 1 day later as above (top). Protein expression was assessed by immunoblotting as above, using anti-GFP (middle) or anti-Tubulin (bottom) antibodies.



Figure 10 shows interactions of Bcl-G<sub>s</sub> and Bcl-G<sub>L</sub> with Bcl-X<sub>L</sub>. 293T cells were transiently transfected with plasmids encoding GFP, GFP-Bcl-G<sub>L</sub>, GFP-Bcl-G<sub>s</sub>, GFP-Bcl-G<sub>s</sub> (DBH3), or GFP-Bcl-G<sub>s</sub> (L218E). Cells were lysed 1  
5 day later and immunoprecipitations were performed using anti-GFP antibody. Immune-complexes (prepared from 2 mg lysate) (top) and lysates (20 µg protein) (bottom) were subjected to SDS-PAGE/immunoblot analysis using anti-Bcl-X<sub>L</sub> (top) and anti-GFP (bottom) antibodies, respectively.

10 Figure 11 shows microscopic evaluation of intracellular distributions of Bcl-G<sub>L</sub> and Bcl-G<sub>s</sub>. Plasmids encoding GFP (A), GFP-Bcl-G<sub>L</sub> (B), GFP-Bcl-G<sub>s</sub> (C), and GFP-Bcl-G<sub>s</sub> (ΔBH3) (D) were transfected into Cos-7  
15 cells. Cells were fixed 1 day later and examined by confocal microscopy.

#### DETAILED DESCRIPTION OF THE INVENTION

In accordance with the present invention, there are provided nucleic acids encoding Bcl-G polypeptides, or functional polypeptide fragments thereof. As used  
20 herein, the term "Bcl-G" refers to sub-family members of the Bcl-2 family of proteins, wherein said Bcl-G comprises a BH3 domain (SEQ ID NOS:5 or 9). The human Bcl-G gene has been found to map to chromosome 12p12.3 (Example II). This region of chromosome 12 is frequently  
25 deleted in cancer cells, in particular in acute lymphoblastic leukemia (ALL) and other solid tumor cells (Baens et al., (1999) Genomics 56:40-50 (1999); Hatta et al., Br. J. Cancer 75:1256-1262 (1997); Kibel et al., Cancer Res. 58:5652-5655 (1998); Baccichet et al., Br. J. Haematol. 99:107-114 (1997); Aissani et al., Leuk. Lymphoma 34:231-239). This region is deleted in a subset  
30 of prostate (approximately 50%), ovarian (approximately

30%) and leukemias (approximately 30%). Therefore, Bcl-G can function as a tumor suppressor. Furthermore, the presence or absence of Bcl-G nucleic acid or polypeptide or changes in Bcl-G nucleic acid or polypeptide expression, can serve as a marker for predisposition or progression of cancer, for example, prostate, ovarian and leukemia. Thus, the invention Bcl-G nucleic acids and/or polypeptides can be used for screening for cancer and/or for developing drug candidates for the treatment of cancer. Invention Bcl-G nucleic acids and/or polypeptides can also be used for discovery of drugs, as disclosed herein, that suppress autoimmunity, inflammation, allergy, allograft rejection, sepsis, and other diseases, including inflammatory diseases.

A new member of the Bcl-2 family was identified, Bcl-G (see Examples). The human *BCL-G* gene consists of 6 exons, resides on chromosome 12p12, and encodes two proteins through alternative mRNA splicing: Bcl-G (long) and Bcl-G (short) consisting of 327 and 252 (length) amino acids, respectively. Bcl-G<sub>L</sub> and Bcl-G<sub>S</sub> are identical in their first 226 amino-acids but diverge thereafter. Among the Bcl-2 Homology (BH) domains previously recognized in Bcl-2 family proteins, the BH3 domain is found in both Bcl-G<sub>L</sub> and Bcl-G<sub>S</sub>, but only the longer Bcl-G<sub>L</sub> protein possesses a BH2 domain. Bcl-G<sub>L</sub> mRNA is expressed widely in normal human tissues, whereas Bcl-G<sub>S</sub> mRNA was found only in testis. Over-expression of Bcl-G<sub>L</sub> or Bcl-G<sub>S</sub> in cells induced apoptosis, but Bcl-G<sub>S</sub> was far more potent than Bcl-G<sub>L</sub>. Apoptosis induction by Bcl-G<sub>S</sub> depended on the BH3 domain, and was suppressed by co-expression of anti-apoptotic Bcl-XL protein. Bcl-XL also co-immunoprecipitated with Bcl-G<sub>S</sub> but not with mutants of Bcl-G<sub>S</sub> in which the BH3 domain was deleted or mutated and not with Bcl-G<sub>L</sub>. Bcl-G<sub>S</sub> was predominantly localized to

cytosolic organelles whereas Bcl-G<sub>L</sub> was diffusely distributed throughout the cytosol. The findings suggest that Bcl-G<sub>L</sub> is likely in a latent state, whereas the shorter Bcl-G<sub>S</sub> protein is constitutively active.

5                   The term "biologically active" or "functional", when used herein as a modifier of an invention Bcl-G, or polypeptide fragment thereof, refers to a polypeptide that exhibits functional characteristics similar to Bcl-G, including those disclosed herein (see Examples I-IX).  
10 As disclosed herein, Bcl-G induces apoptosis (see Example IV). Therefore, one function of Bcl-G is a pro-apoptotic function. The pro-apoptotic function of Bcl-G is inhibited by co-expression of the anti-apoptotic protein Bcl-2 (Example IV). Therefore, another function of Bcl-G  
15 is modulation by or interaction with an anti-apoptotic protein such as for example, Bcl-2 family member, including Bcl-2 or Bcl-X<sub>L</sub>, and the like. Bcl-G can function to heterodimerize with a Bcl-2 family member, thereby modulating the apoptotic activity of Bcl-G and/or  
20 the Bcl-2 family member. For example, the interaction of Bcl-G<sub>S</sub> with Bcl-X<sub>L</sub> was found to be BH3 domain dependent, and, thus, the pro-apoptotic activity of Bcl-G<sub>S</sub> correlates with its ability to bind Bcl-X<sub>L</sub> (see Example VI).

                  Bcl-G is also contemplated herein as having the  
25 ability to function as an ion channel. Additionally, Bcl-G is contemplated herein as having the ability to function target to mitochondria, for example, for example, by binding directly to mitochondria or via binding to a protein that is associated with mitochondria  
30 such as Bcl-2 or Bcl-X<sub>L</sub>. Bcl-G can also function to bind adenine nucleotide transporter (ANT) and to other proteins such as voltage-dependent anion channel (VDAC).

Because Bcl-G is located on chromosome 12 in a region that is frequently deleted in cancer cells (Example II) it is contemplated herein that Bcl-G functions as a tumor suppressor. Another functional activity of Bcl-G is the ability to act as an immunogen for the production of polyclonal and monoclonal antibodies that bind specifically to an invention Bcl-G. Thus, an invention nucleic acid encoding Bcl-G will encode a polypeptide specifically recognized by an antibody that also specifically recognizes the Bcl-G protein including the amino acid sequence, set forth in SEQ ID NOS:2, 4 or 42. Such immunologic activity can be assayed by any method known to those of skill in the art. Therefore, Bcl-G functional fragments include polypeptide fragments that function as immunogens for generating a Bcl-G-specific antibody and fragments that specifically bind to a Bcl-G-specific antibody.

Bcl-2 family proteins are central regulators of apoptosis (reviewed in Reed, J. C., Nature, 387:773-776 (1997); Adams & Cory, Science, 281:1322-1326 (1998); Gross et al., Genes Dev., 13:1899-1911 (1999)). Bcl-2 family proteins are conserved throughout the animal kingdom, with homologues identified in both vertebrates and invertebrates. These proteins contain up to four conserved Bcl-2 Homology (BH) domains, BH1, BH2, BH3, and BH4, which are recognized by their amino-acid sequence similarity. Both anti-apoptotic and pro-apoptotic Bcl-2 family proteins have been identified. These proteins control cell life-death decisions through their effects on events such as mitochondrial release of proteins involved in activation of caspase-family cell death proteases (reviewed in Gross et al., Genes Dev., 13:1899-1911 (1999); Green & Reed, Science, 281:1309-1312 (1998); Kroemer & Reed, Nature Medicine, 6:513-519 (2000)). Many

Bcl-2 family proteins are capable of physically interacting with each other, forming a complex network of homo- and heterodimers, and these physical interactions sometimes play important roles in the opposing effects of pro- and anti-apoptotic members of the family.

The pro-apoptotic members of the Bcl-2 family can be broadly classified into two groups. One group, including Bax, Bak, and Bok in humans, shares structural similarity with the pore-forming domains of certain bacterial toxins and is capable of forming pores in synthetic membranes *in vitro* (Schendel et al., Cell Death Differ., 5:372-380 (1998); Antonsson et al., Science, 277:370-372 (1997); Schlesinger et al., Proc. Natl. Acad. Sci. USA, 94:11357-11362 (1997); Shimizu et al., J Biol Chem., 16:12321-12325 (2000)). These proteins exhibit cytotoxic effects independently of their ability to bind other Bcl-2 family proteins, including Bcl-2 and other cytoprotective members of the family such as Bcl-X<sub>L</sub>, Bcl-W, Bfl-1, and Mcl-1. The second group of pro-apoptotic Bcl-2 family proteins varies widely in their amino-acid sequences, often containing only a single region of similarity, the BH3 domain. These "BH3-only" proteins appear to possess no intrinsic or autonomous cytodestructive activity, and instead operate as trans-dominant inhibitors of the survival proteins. Their antagonism of proteins such as Bcl-2 and Bcl-X<sub>L</sub> depends on binding via their BH3 domains to a hydrophobic pocket on target anti-apoptotic proteins (Kelekar & Thompson, Trends Cell Biol., 8:324-330 (1998)).

Gene knock-out studies in mice have demonstrated non-redundant roles for various Bcl-2 family genes in regulating cell life and death in specific tissues or under particular physiological or pathological

circumstances (Veis et al., Cell, 75:229-240 (1993); Motoyama et al., Science, 267:1506-1510 (1995); Knudson et al., Science, 270:96-99 (1995); Bouillet et al., Science, 286:1735-8 (1999); Yin et al., Nature, 400:886-891 (1999)). Thus, it is important to identify all members of the Bcl-2 family and to delineate the cellular contexts in which they contribute to apoptosis regulation. As disclosed herein, a new member of the Bcl-2 family, Bcl-G, has been cloned and characterized.

10           The nucleic acid molecules described herein are useful for producing invention proteins, when such nucleic acids are incorporated into a variety of protein expression systems known to those of skill in the art. In addition, such nucleic acid molecules or fragments  
15           thereof can be labeled with a readily detectable substituent and used as hybridization probes for assaying for the presence and/or amount of an invention Bcl-G gene or mRNA transcript in a given sample. The nucleic acid molecules described herein, and fragments thereof, are  
20           also useful as primers and/or templates in a PCR reaction for amplifying genes encoding invention proteins described herein.

          The term "nucleic acid", also referred to as polynucleotides, encompasses ribonucleic acid (RNA) or  
25           deoxyribonucleic acid (DNA), probes, oligonucleotides, and primers and can be single stranded or double stranded. DNA can be either complementary DNA (cDNA) or genomic DNA, and can represent the sense strand, the anti-sense strand or both. Examples of nucleic acids are  
30           RNA, cDNA, or isolated genomic DNA encoding an Bcl-G polypeptide. Such nucleic acids include, but are not limited to, nucleic acids comprising substantially the same nucleotide sequence as set forth in SEQ ID NOS:1, 3

or 41. In general, a genomic sequence of the invention includes regulatory regions such as promoters, enhancers, and introns that are outside of the exons encoding a Bcl-G but does not include proximal genes that do not encode Bcl-G.

Use of the terms "isolated" and/or "purified" in the present specification and claims as a modifier of DNA, RNA, polypeptides or proteins means that the DNA, RNA, polypeptides or proteins so designated have been produced in such form by the hand of man, and thus are separated from their native *in vivo* cellular environment.

As employed herein, the term "substantially the same nucleotide sequence" refers to DNA having sufficient identity to the reference polynucleotide, such that it will hybridize to the reference nucleotide under moderately stringent hybridization conditions. In one embodiment, DNA having substantially the same nucleotide sequence as the reference nucleotide sequence encodes substantially the same amino acid sequence as that set forth in any of SEQ ID NOS:2, 4 or 42. In another embodiment, DNA having "substantially the same nucleotide sequence" as the reference nucleotide sequence has at least 60% identity with respect to the reference nucleotide sequence. DNA having substantially the same nucleotide sequence can have at least 70%, at least 90%, or at least 95% identity to the reference nucleotide sequence.

As used herein, a "modification" of a nucleic acid can also include one or several nucleotide additions, deletions, or substitutions with respect to a reference sequence. A modification of a nucleic acid can include substitutions that do not change the encoded

amino acid sequence due to the degeneracy of the genetic code. Such modifications can correspond to variations that are made deliberately, or which occur as mutations during nucleic acid replication.

5 Exemplary modifications of the recited Bcl-G sequences include sequences that correspond to homologs of other species, including mammalian species such as mouse, primates, including monkey and baboon, rat, rabbit, bovine, porcine, ovine, canine, feline, or other  
10 animal species. The corresponding Bcl-G sequences of non-human species can be determined by methods known in the art, such as by PCR or by screening genomic, cDNA or expression libraries.

Another exemplary modification of the invention  
15 Bcl-G can correspond to splice variant forms of the Bcl-G nucleotide sequence. Additionally, a modification of a nucleotide sequence can include one or more non-native nucleotides, having, for example, modifications to the base, the sugar, or the phosphate portion, or having a  
20 modified phosphodiester linkage. Such modifications can be advantageous in increasing the stability of the nucleic acid molecule.

Furthermore, a modification of a nucleotide  
25 sequence can include, for example, a detectable moiety, such as a radiolabel, a fluorochrome, a ferromagnetic substance, a luminescent tag or a detectable binding agent such as biotin. Such modifications can be advantageous in applications where detection of a Bcl-G nucleic acid molecule is desired.

30 The invention also encompasses nucleic acids which differ from the nucleic acids shown in SEQ ID NOS:



1, 3 or 41, but which have the same phenotype.

Phenotypically similar nucleic acids are also referred to as "functionally equivalent nucleic acids". As used herein, the phrase "functionally equivalent nucleic acids" encompasses nucleic acids characterized by slight and non-consequential sequence variations that will function in substantially the same manner to produce the same protein product(s) as the nucleic acids disclosed herein. In particular, functionally equivalent nucleic acids encode polypeptides that are the same as those encoded by the nucleic acids disclosed herein or that have conservative amino acid variations. For example, conservative variations include substitution of a non-polar residue with another non-polar residue, or substitution of a charged residue with a similarly charged residue. These variations include those recognized by skilled artisans as those that do not substantially alter the tertiary structure of the protein.

Further provided are nucleic acids encoding Bcl-G polypeptides that, by virtue of the degeneracy of the genetic code, do not necessarily hybridize to the invention nucleic acids under specified hybridization conditions. As used herein, the term "degenerate" refers to codons that differ in at least one nucleotide from a reference nucleic acid, but encode the same amino acids as the reference nucleic acid. Nucleic acids encoding the invention Bcl-G polypeptides can be comprised of nucleotides that encode substantially the same amino acid sequence as set forth in SEQ ID NOS:2, 4 or 42.

The invention provides an isolated nucleic acid encoding a Bcl-G polypeptide, or a functional fragment thereof. The invention also provides an isolated nucleic

acid encoding a Bcl-G polypeptide, or a functional fragment thereof, comprising a nucleic acid selected from:

5 (a) nucleic acid encoding the amino acid sequence set forth in SEQ ID NOS:2, 4 or 42, or

10 (b) nucleic acid that hybridizes to the nucleic acid of (a) under moderately stringent conditions, wherein said nucleic acid contiguously encodes biologically active Bcl-G, or

(c) nucleic acid degenerate with respect to either (a) or (b) above, wherein said nucleic acid encodes biologically active Bcl-G.

15 In one embodiment, preferred Bcl-G polypeptide include a long form termed Bcl-G<sub>L</sub> and a short form termed Bcl-G<sub>S</sub>. Bcl-G<sub>L</sub> contains a BH3 and a BH2 domain, whereas Bcl-G<sub>S</sub> contains only a BH3 domain. Bcl-G<sub>S</sub> has been found to possess pro-apoptotic activity similar to Bax (see Example III).

20 Hybridization refers to the binding of complementary strands of nucleic acid, for example, sense:antisense strands or probe:target-nucleic acid to each other through hydrogen bonds, similar to the bonds that naturally occur in chromosomal DNA. Stringency  
25 levels used to hybridize a given probe with target-DNA can be readily varied by those of skill in the art.

30 The phrase "stringent hybridization" is used herein to refer to conditions under which polynucleic acid hybrids are stable. As known to those of skill in the art, the stability of hybrids is reflected in the

melting temperature ( $T_m$ ) of the hybrids. In general, the stability of a hybrid is a function of sodium ion concentration and temperature. Typically, the hybridization reaction is performed under conditions of lower stringency, followed by washes of varying, but higher, stringency. Reference to hybridization stringency relates to such washing conditions.

As used herein, the phrase "moderately stringent hybridization" refers to conditions that permit target-nucleic acid to bind a complementary nucleic acid. The hybridized nucleic acids will generally have at least about 60% identity, at least about 75% identity, more at least about 85% identity; or at least about 90% identity. Moderately stringent conditions are conditions equivalent to hybridization in 50% formamide, 5X Denhart's solution, 5X SSPE, 0.2% SDS at 42°C, followed by washing in 0.2X SSPE, 0.2% SDS, at 42°C.

The phrase "high stringency hybridization" refers to conditions that permit hybridization of only those nucleic acid sequences that form stable hybrids in 0.018M NaCl at 65°C, for example, if a hybrid is not stable in 0.018M NaCl at 65°C, it will not be stable under high stringency conditions, as contemplated herein. High stringency conditions can be provided, for example, by hybridization in 50% formamide, 5X Denhart's solution, 5X SSPE, 0.2% SDS at 42°C, followed by washing in 0.1X SSPE, and 0.1% SDS at 65°C.

The phrase "low stringency hybridization" refers to conditions equivalent to hybridization in 10% formamide, 5X Denhart's solution, 6X SSPE, 0.2% SDS at 22°C, followed by washing in 1X SSPE, 0.2% SDS, at 37°C. Denhart's solution contains 1% Ficoll, 1%

polyvinylpyrrolidone, and 1% bovine serum albumin (BSA).  
20X SSPE (sodium chloride, sodium phosphate, ethylene  
diamide tetraacetic acid (EDTA)) contains 3M sodium  
chloride, 0.2M sodium phosphate, and 0.025 M (EDTA).

5 Other suitable moderate stringency and high stringency  
hybridization buffers and conditions are well known to  
those of skill in the art and are described, for example,  
in Sambrook et al., Molecular Cloning: A Laboratory  
Manual, 2nd ed., Cold Spring Harbor Press, Plainview, New  
10 York (1989); and Ausubel et al., *supra*, 1999). Nucleic  
acids encoding polypeptides hybridize under moderately  
stringent or high stringency conditions to substantially  
the entire sequence, or substantial portions, for  
example, typically at least 15-30 nucleotides of the  
15 nucleic acid sequence set forth in SEQ ID NOS:1, 3 or 41.

The invention also provides a modification of a  
Bcl-G nucleotide sequence that hybridizes to a Bcl-G  
nucleic acid molecule, for example, a nucleic acid  
molecule referenced as SEQ ID NOS:1, 3 or 41, under  
20 moderately stringent conditions. Modifications of Bcl-G  
nucleotide sequences, where the modification has at least  
60% identity to a Bcl-G nucleotide sequence, are also  
provided. The invention also provides modification of a  
Bcl-G nucleotide sequence having at least 65% identity,  
25 at least 70% identity, at least 75% identity, at least  
80% identity, at least 85% identity, at least 90%  
identity, or at least 95% identity.

Identity of any two nucleic acid sequences can  
be determined by those skilled in the art based, for  
30 example, on a BLAST 2.0 computer alignment, using default  
parameters. BLAST 2.0 searching is available at  
<http://www.ncbi.nlm.nih.gov/gorf/bl2.html>., as described  
by Tatiana et al., FEMS Microbiol Lett. 174:247-250

(1999); Altschul et al., Nucleic Acids Res., 25:3389-3402 (1997).

5 One means of isolating a nucleic acid encoding a Bcl-G polypeptide is to probe a cDNA library or genomic library with a natural or artificially designed nucleic acid probe using methods well known in the art. Nucleic acid probes derived from the Bcl-G gene are particularly useful for this purpose. DNA and cDNA molecules that encode Bcl-G polypeptides can be used to obtain  
10 complementary genomic DNA, cDNA or RNA from mammals, for example, human, mouse, rat, rabbit, pig, and the like, or other animal sources, or to isolate related cDNA or genomic clones by the screening of cDNA or genomic libraries, by methods well known in the art (see, for example, Sambrook et al., supra, 1989; Ausubel et al.,  
15 supra, 1999).

The invention additionally provides a nucleic acid that hybridizes under high stringency conditions to the Bcl-G coding portion of any of SEQ ID NOS:1, 3 or 41.  
20 The invention also provides a nucleic acid having a nucleotide sequence the same or substantially the same as set forth in any of SEQ ID NOS:1, 3 or 41.

The invention also provides a method for identifying nucleic acids encoding a mammalian Bcl-G by  
25 contacting a sample containing nucleic acids with one or more Bcl-G oligonucleotides, wherein the contacting is effected under high stringency hybridization conditions, and identifying a nucleic acid that hybridizes to the oligonucleotide. The invention additionally provides a  
30 method of detecting a Bcl-G nucleic acid molecule in a sample by contacting the sample with two or more Bcl-G

oligonucleotides, amplifying a nucleic acid molecule, and detecting the amplification. The amplification can be performed, for example, using PCR. The invention further provides oligonucleotides that function as single  
5 stranded nucleic acid primers for amplification of a Bcl-G nucleic acid, wherein the primers comprise a nucleic acid sequence derived from the nucleic acid sequences set forth as SEQ ID NOS:1, 3 or 41.

In accordance with a further embodiment of the present invention, optionally labeled Bcl-G-encoding  
10 nucleic acids, or fragments thereof, can be employed to probe a library, for example, a cDNA or genomic library, and the like for additional nucleic acid sequences encoding novel Bcl-G polypeptides. Construction of  
15 suitable cDNA libraries is well-known in the art. Screening of such a cDNA library is initially carried out under low-stringency conditions, which comprise a temperature of less than about 42°C, a formamide concentration of less than about 50%, and a moderate to  
20 low salt concentration.

Presently preferred probe-based screening conditions comprise a temperature of about 37°C, a formamide concentration of about 20%, and a salt concentration of about 5X sodium chloride, sodium citrate  
25 (SSC; 20X SSC contains 3M sodium chloride, 0.3M sodium citrate, pH 7.0). Such conditions will allow the identification of sequences having a substantial degree of similarity with the probe sequence, without requiring perfect identity. The phrase "substantial similarity"  
30 refers to sequences which share at least 50% identity. Hybridization conditions are selected which allow the identification of sequences having at least 70% identity with the probe, while discriminating against sequences

having a lower degree of identity with the probe. As a result, nucleic acids having substantially the same nucleotide sequence as SEQ ID NOS:1, 3 or 41 are obtained.

5                   As used herein, a nucleic acid "probe" is single-stranded nucleic acid, or analogs thereof, that has a sequence of nucleotides that includes at least 14, at least 20, at least 50, at least 100, at least 200, at least 300, at least 400, or at least 500 contiguous bases  
10 that are the same as or the complement thereof, any contiguous bases set forth in any of SEQ ID NOS:1, 3 or 41. In addition, the entire cDNA encoding region of an invention Bcl-G, or the entire sequence corresponding to SEQ ID NOS:1, 3 or 41 can be used as a probe. Probes can  
15 be labeled by methods well-known in the art, as described hereinafter, and used, for example, in various diagnostic kits.

                  The invention additionally provides a Bcl-G oligonucleotide comprising between 15 and 300 contiguous  
20 nucleotides of SEQ ID NOS:1, 3 or 41, or the anti-sense strand thereof. As used herein, the term "oligonucleotide" refers to a nucleic acid molecule that includes at least 15 contiguous nucleotides from a reference nucleotide sequence, can include at least 16,  
25 17, 18, 19, 20 or at least 25 contiguous nucleotides, and often includes at least 30, 40, 50, 60, 70, 80, 90, 100, 125, 150, 175, 200, 225, 250, 275, 300, 325, up to 350 contiguous nucleotides from the reference nucleotide sequence. The reference nucleotide sequence can be the  
30 sense strand or the anti-sense strand.

                  The Bcl-G oligonucleotides of the invention that contain at least 15 contiguous nucleotides of a

reference Bcl-G nucleotide sequence are able to hybridize to Bcl-G under moderately stringent hybridization conditions and thus can be advantageously used, for example, as probes to detect Bcl-G DNA or RNA in a sample, and to detect splice variants thereof; as sequencing or PCR primers; as antisense reagents to block transcription of Bcl-G RNA in cells; or in other applications known to those skilled in the art in which hybridization to a Bcl-G nucleic acid molecule is desirable.

It is understood that a Bcl-G nucleic acid molecule, as used herein, specifically excludes previously known nucleic acid molecules consisting of nucleotide sequences having identity with the Bcl-G nucleotide sequence (SEQ ID NOS:1, 3 or 41), such as Expressed Sequence Tags (ESTs), Sequence Tagged Sites (STSs) and genomic fragments, deposited in public databases such as the nr, dbest, dbsts, gss and htgs databases, which are available for searching at <http://www.ncbi.nlm.nih.gov/blast/blast.cgi?Jform=0>, using the program BLASTN 2.0.9 described by Altschul et al., Nucleic Acids Res. 25:3389-3402 (1997).

In particular, a Bcl-G nucleic acid molecule specifically excludes nucleic acid molecules consisting of any of the nucleotide sequences having the Genbank (gb), EMBL (emb) or DDBJ (dbj) accession numbers described below. Similarly, a Bcl-G polypeptide fragment specifically excludes the amino acid fragments encoded by the nucleotide sequences having the GenBank accession numbers described below. GenBank accession numbers specifically excluded include AC005903, AC007439, AW000827, AA399486, AW001213, AI478889, AA400686, AA398276, AI240211, and AA536718. The human BAC



referenced as GenBank accession No. AC007537 is also specifically excluded from a Bcl-G nucleic acid.

5 The isolated Bcl-G nucleic acid molecules of the invention can be used in a variety of diagnostic and therapeutic applications. For example, the isolated Bcl-G nucleic acid molecules of the invention can be used as probes, as described above; as templates for the recombinant expression of Bcl-G polypeptides; or in screening assays such as two-hybrid assays to identify  
10 cellular molecules that bind Bcl-G.

Another useful method for producing a Bcl-G nucleic acid molecule of the invention involves amplification of the nucleic acid molecule using PCR and Bcl-G oligonucleotides and, optionally, purification of  
15 the resulting product by gel electrophoresis. Either PCR or RT-PCR can be used to produce a Bcl-G nucleic acid molecule having any desired nucleotide boundaries. Desired modifications to the nucleic acid sequence can also be introduced by choosing an appropriate  
20 oligonucleotide primer with one or more additions, deletions or substitutions. Such nucleic acid molecules can be amplified exponentially starting from as little as a single gene or mRNA copy, from any cell, tissue or species of interest.

25 The invention thus provides methods for detecting Bcl-G nucleic acid in a sample. The methods of detecting Bcl-G nucleic acid in a sample can be either qualitative or quantitative, as desired. For example, the presence, abundance, integrity or structure of a Bcl-G  
30 can be determined, as desired, depending on the assay format and the probe used for hybridization or primer pair chosen for application.

Useful assays for detecting Bcl-G nucleic acid based on specific hybridization with an isolated Bcl-G nucleic acid molecule are well known in the art and include, for example, *in situ* hybridization, which can be used to detect altered chromosomal location of the nucleic acid molecule, altered gene copy number, and RNA abundance, depending on the assay format used. Other hybridization assays include, for example, Northern blots and RNase protection assays, which can be used to determine the abundance and integrity of different RNA splice variants, and Southern blots, which can be used to determine the copy number and integrity of DNA. A Bcl-G hybridization probe can be labeled with any suitable detectable moiety, such as a radioisotope, fluorochrome, chemiluminescent marker, biotin, or other detectable moiety known in the art that is detectable by analytical methods.

Useful assays for detecting a Bcl-G nucleic acid in a sample based on amplifying a Bcl-G nucleic acid with two or more Bcl-G oligonucleotides are also well known in the art, and include, for example, qualitative or quantitative polymerase chain reaction (PCR); reverse-transcription PCR (RT-PCR); single strand conformational polymorphism (SSCP) analysis, which can readily identify a single point mutation in DNA based on differences in the secondary structure of single-strand DNA that produce an altered electrophoretic mobility upon non-denaturing gel electrophoresis; and coupled PCR, transcription and translation assays, such as a protein truncation test, in which a mutation in DNA is determined by an altered protein product on an electrophoresis gel. Additionally, the amplified Bcl-G nucleic acid can be sequenced to detect mutations and mutational hot-spots, and specific assays for large-scale screening of samples to identify

such mutations can be developed.

The invention further provides an isolated Bcl-G polypeptide, or a functional fragment thereof, encoded by a Bcl-G nucleic acid of the invention. For example,  
5 the invention provides a polypeptide comprising the same or substantially the same amino acid sequence as Bcl-G<sub>L</sub> (SEQ ID NO:2) or Bcl-G<sub>S</sub> (SEQ ID NO:4). Also provided is a Bcl-G polypeptide encoded by a nucleotide sequence comprising the same or substantially the same nucleotide  
10 sequence as set forth in SEQ ID NOs:1 or 3. Additionally provided is mouse Bcl-G nucleotide sequence set forth as SEQ ID NO:41 (see Example IX).

Described herein is a new member of the *BCL-2* gene family in humans, *BCL-G* (see Examples I-VIII). The  
15 *BCL-G* gene potentially encodes two protein products, Bcl-G<sub>L</sub> and Bcl-G<sub>S</sub>. Bcl-2 family proteins contain up to four conserved BH domains. The shorter Bcl-G<sub>S</sub> protein contains only the BH3 domains, similar to several other pro-apoptotic Bcl-2 family proteins, including Bad, Hrk, Bik,  
20 Bim, Apr, and Eg11 (reviewed in Kelekar & Thompson, Trends Cell Biol., 8:324-330 (1998); Reed, J. Oncogene, 17:3225-3236 (1998)). In contrast, the longer Bcl-G<sub>L</sub> protein contains a BH2 and BH3 domain. No other examples of Bcl-2 family proteins are known which combine BH2 and  
25 BH3 domain in the absence of BH1. Though the Bad protein was originally suggested to contain a BH2 domain (Yang et al., Blood, 84(Suppl.1):373a-380a (1994)), and has been shown to possess the BH3 domain, inspection of the BH2 region reveals very little similarity of amino-acid  
30 sequence with (Ottillie et al., J. Biol. Chem., 272:30866-30872 (1997)) other BH2 domains. In contrast, the BH2 of Bcl-G<sub>L</sub> contains a stretch of 8 of 8 residues showing identity or conservative amino-acid substitutions with

the BH2 domains of other family members. By comparison, the Bad sequence reveals only 3 of 8 identical or similar amino-acids in the same region. Thus, Bcl-G<sub>L</sub> defines a novel structural variant within the Bcl-2 family of apoptosis-regulating proteins.

The production of different protein isoforms by alternative mRNA splicing is a common feature of *BCL-2* family genes, including *BCL-2*, *Bcl-X*, *MCL-1*, *BAX*, and *BIM* (Tsujiimoto & Croce, Proc. Natl. Acad. Sci. USA, 83:5214-5218 (1986); O'Connor et al., EMBO J., 17:384-395 (1998); Boise et al., Cell, 74:597-608 (1993); Oltvai et al., Cell, 74:609-619 (1993); Bingle et al., J. Biol. Chem., 275:22136-22146 (2000)). Unlike *BCL-X*, which encodes a longer and short protein, Bcl-X<sub>L</sub> and Bcl-X<sub>S</sub>, possessing anti-apoptotic and pro-apoptotic functions, respectively, the longer isoform of Bcl-G did not display anti-apoptotic activity. When over-expressed, Bcl-G<sub>L</sub> induced modest and variable increases in apoptosis, whereas the shorter Bcl-G<sub>S</sub> protein consistently exhibited potent cytotoxic activity. This behavior is reminiscent of the proteins encoded by the *BIM* gene, which include Bim-short (Bim<sub>S</sub>), Bim-long (Bim<sub>L</sub>) and Bim-Extra-Long (Bim<sub>EL</sub>) (O'Connor et al., EMBO J., 17:384-395 (1998)). The longer proteins, Bim<sub>L</sub> and Bim<sub>EL</sub>, are sequestered in complexes with dynein light-chain (DLC) in association with microtubules, thus preventing them from interacting with target proteins such as Bcl-X<sub>L</sub> on the surface of mitochondria and other organelles (Puthalakath et al., Mol. Cell, 3:287-96 (1999)). In contrast, because the shortest isoform, Bim<sub>S</sub>, does not associate with DLC, it is free to interact with Bcl-X<sub>L</sub>, Bcl-2, and other survival proteins and hence displays far more potent apoptotic activity when over-expressed in cells. By analogy, the longer Bcl-G<sub>L</sub> protein could be sequestered in an inactive

complex with an unidentified protein.

Besides interactions with sequestering proteins, the activity of pro-apoptotic Bcl-2 family proteins can be suppressed by other mechanisms, including post-translational modifications. For example, the Bad protein is inactivated by phosphorylation. This protein can be directly or indirectly phosphorylated by several protein kinases, including PKA, PKB (Akt), Raf1, and Pak1, thus preventing it from dimerizing with target proteins such as Bcl-2 and Bcl-X<sub>L</sub> (reviewed in Reed, J. Oncogene, 17:3225-3236 (1998); Datta et al., Genes Dev., 13:2905-2927 (1999)). The intracellular location of Bad varies, depending on its phosphorylation state, with phosphorylated Bad residing in the cytosol and unphosphorylated Bad associated with mitochondria and other intracellular organelles where Bcl-2 and Bcl-X<sub>L</sub> are located. In this regard, the Bcl-G<sub>L</sub> protein contains candidate phosphorylation sites for protein kinase A (PKA) and protein kinase C (PKC), including some not found in Bcl-G<sub>S</sub>. However, *in vivo* phosphorylation of Bcl-G<sub>L</sub> has not been observed in pilot experiments.

Another post-translational modification shown previously to activate latent pro-apoptotic Bcl-2 family proteins is proteolysis. Specifically, the Bid protein contains a N-terminal domain of ~56 amino-acids that masks its BH3 domain, reducing its ability to dimerize with other Bcl-2 family proteins. Upon cleavage by caspases, however, removal of the N-terminal domain exposes the BH3 domain and is associated with translocation of Bid from the cytosol to mitochondria, where it induces cytochrome c release and apoptosis (Li et al., Cell, 94:491-501 (1998); Luo et al., Cell, 94:481-490 (1998)). While Bcl-G<sub>L</sub> contains candidate

5 caspase recognition sites, no significant cleavage of Bid has been observed *in vitro* using purified active caspases or in cells during apoptosis. It is possible, however, that a specific caspase not yet tested is capable of cleaving and activating Bcl-G<sub>L</sub>.

10           Though possessing no hydrophobic region that might anchor it in membranes, the Bcl-G<sub>S</sub> protein was constitutively associated with intracellular organelles. Interestingly, removal of the BH3 domain did not  
15 interfere with organelle-targeting of Bcl-G<sub>S</sub>, but did abolish dimerization with Bcl-X<sub>L</sub>. Thus, the BH3 domain apparently is not responsible for association of Bcl-G<sub>S</sub> with intracellular organelles. This BH3-independent targeting of Bcl-G<sub>S</sub> differs from some other "BH3-only"  
20 Bcl-2 family proteins such as Bad, where it has been observed that removal of the BH3 domain abrogates binding to anti-apoptotic Bcl-2 family proteins as well as association with mitochondria (Zha et al., J. Biol. Chem., 272:24101-24104 (1997)).

25           The *BCL-G* gene resides on chromosome 12p12, a region deleted in ~50% of prostate cancers, ~30% of ovarian cancers, and ~30% of childhood acute lymphocytic leukemias (ALLs) (Kibel et al., J Urol., 1:192-196 (2000); Aissani et al., Leuk Lymphoma, 34:231-239 (1999);  
30 Hatta et al., Br J Cancer, 75:1256-1262 (1997)). Given that at least one of the protein products of the *BCL-G* gene exhibits pro-apoptotic function, it is possible that *BCL-G* represents a tumor suppressor gene. However, thus far, somatic mutations in the exons of *BCL-G* have not  
35 been detected nor evidence of deletion of both *BCL-G* alleles in tumor cell lines or primary tumor specimens tested so far. Further studies are required therefore to

determine whether loss of *BCL-G* expression occurs in tumors by means other than somatic alterations in gene structure and DNA sequence, such as changes in gene methylation or aberrant transcriptional or post-transcriptional regulation.

Investigation of the tissue-distribution of *Bcl-G<sub>L</sub>* and *Bcl-G<sub>S</sub>* mRNAs by RT-PCR revealed that *Bcl-G<sub>L</sub>* mRNA is found in several normal adult tissues, whereas *Bcl-G<sub>S</sub>* was detected only in testis. This finding indicates tissue-specific regulation of *Bcl-G<sub>S</sub>* mRNA splicing. Tissue-specific splicing of other *Bcl-2* family mRNAs has been observed previously. For example, *Bcl-X* mRNA splicing events which generate the pro-apoptotic *Bcl-X<sub>S</sub>* protein occur in the thymus during T-cell ontogeny and in the mammary gland during post-lactation involution, in association with extensive apoptosis induction (Boise et al., *Cell*, 74:597-608 (1993); Heermeier et al., *Mech. Dev.*, 56:197-207 (1996)). Additional studies are performed to assess differential mRNA splicing patterns of *Bcl-G* transcripts during fetal development and following various scenarios in the adult where apoptosis occurs as part of a normal physiological response or an abnormal pathological reaction to environmental insults.

As employed herein, the term "substantially the same amino acid sequence" refers to amino acid sequences having at least about 70% identity with respect to the reference amino acid sequence, and retaining comparable functional and biological activity characteristic of the protein defined by the reference amino acid sequence. Preferably, proteins having "substantially the same amino acid sequence" will have at least about 80%, more preferably 90% amino acid identity with respect to the

reference amino acid sequence; with greater than about 95% amino acid sequence identity being especially preferred. It is recognized, however, that polypeptides, or encoding nucleic acids, containing less than the described levels of sequence identity arising as splice variants or that are modified by conservative amino acid substitutions, or by substitution of degenerate codons are also encompassed within the scope of the present invention.

Also encompassed by the term Bcl-G are functional fragments or polypeptide analogs thereof. The term "functional fragment" refers to a peptide fragment that is a portion of a full length Bcl-G protein, provided that the portion has a biological activity, as defined herein, that is characteristic of the corresponding full length protein. Thus, the invention also provides functional fragments of invention Bcl-G proteins, which can be identified using the binding and routine methods, such as bioassays described herein. A Bcl-G polypeptide functional fragment can be a BH3 or BH2 domain, for example, a BH3 domain referenced as SEQ ID NOS:5 or 9 or a BH2 domain referenced as SEQ ID NOS:6 or 18. The BH3 domain of Bcl-G is 33% identical to the BH3 domain of Bcl-2, 44% identical to the BH3 domain of Bcl-X<sub>L</sub>, and 66% identical to the BH3 domain of Bax.

In addition, a functional fragment of a Bcl-G polypeptide can be Bax homology region. A region upstream of the BH3 domain shares a high degree of homology with Bax, including a 12 amino acid residue motif that is 70% identical between Bcl-G and Bax. Therefore, such a Bax homology region can function similarly to Bax, for example, as a possible binding domain. The N-terminal 150 amino acids of Bcl-G are not



similar to any known amino acid sequence available in public databases. Therefore, the N-terminal region of Bcl-G can function as Bcl-G-specific functional domain that confers a biological activity that is specific for Bcl-G relative to other members of the Bcl-2 family.

The invention also provides a chimeric protein comprising a domain selected from the group consisting of BH3 (SEQ ID NOS:5 or 9) and BH2 (SEQ ID NOS:6 or 18). A chimeric protein comprising a Bcl-G functional domain can be generated, for example, by recombinantly expressing a Bcl-G domain such as BH2 or BH3 fused to another polypeptide. Alternatively, the Bcl-G functional domain can be expressed as a fusion to another polypeptide.

In another embodiment of the invention, Bcl-G-containing chimeric proteins are provided comprising an invention Bcl-G, or fragments thereof, having the sequence of SEQ ID NO:2, SEQ ID NO:4, or SEQ ID NO:42, and further comprising one or more sequences from a heterologous protein. Sequences from heterologous proteins with which the Bcl-G or functional fragment thereof are fused can include, for example, glutathione-S-transferase, an antibody, or other proteins or functional fragments thereof which facilitate recovery of the chimera. Further proteins with which the Bcl-G or functional fragment thereof are fused will include, for example, luciferase, green fluorescent protein, an antibody, or other proteins or functional fragments thereof which facilitate identification of the chimera. Still further proteins with which the Bcl-G or functional fragment thereof are fused will include, for example, the LexA DNA binding domain, ricin,  $\alpha$ -sarcin, an antibody, or other proteins which have therapeutic properties or other biological activity.

As such chimeric proteins include sequences from two different proteins, the resultant amino acid sequence of the chimeric protein will typically be a non-naturally occurring sequence. Thus, in accordance with this embodiment of the invention, there are provided chimeric proteins comprising an invention Bcl-G, or fragments thereof, having the sequence of SEQ ID NO:2, SEQ ID NO:4, or SEQ ID NO:42, or a fragment thereof, provided the sequence of the chimeric protein is not naturally occurring.

In another embodiment of the invention, there are provided hetero-oligomers comprising invention Bcl-G polypeptides and fragments thereof, invention Bcl-G-containing proteins, Bcl-G-containing chimeric proteins, or combinations thereof. As disclosed herein, Bcl-G contains a BH3 domain, which functions as a ligand to bind Bcl-2 family members (Example I). Bcl-G can function to bind Bcl-2 family members. Thus, hetero-oligomers comprising invention Bcl-G polypeptides (SEQ ID NOS:2, 4 or 42) and fragments thereof, invention Bcl-G-containing proteins, Bcl-G-containing chimeric proteins, or combinations thereof, and further comprising Bcl-2 family members such as Bcl-2, Bcl-X<sub>L</sub> or other Bcl-2 family members are provided.

As used herein, the term "polypeptide" when used in reference to Bcl-G is intended to refer to a peptide or polypeptide of two or more amino acids. The term "polypeptide analog" includes any polypeptide having an amino acid residue sequence substantially the same as a sequence specifically described herein in which one or more residues have been conservatively substituted with a functionally similar residue and which displays the ability to functionally mimic a Bcl-G as described

herein. A "modification" of a Bcl-G polypeptide also encompasses conservative substitutions of a Bcl-G polypeptide amino acid sequence. Conservative substitutions of encoded amino acids include, for example, amino acids that belong within the following groups: (1) non-polar amino acids (Gly, Ala, Val, Leu, and Ile); (2) polar neutral amino acids (Cys, Met, Ser, Thr, Asn, and Gln); (3) polar acidic amino acids (Asp and Glu); (4) polar basic amino acids (Lys, Arg and His); and (5) aromatic amino acids (Phe, Trp, Tyr, and His). Other minor modifications are included within Bcl-G polypeptides so long as the polypeptide retains some or all of its function as described herein.

The amino acid length of functional fragments or polypeptide analogs of the present invention can range from about 5 amino acids up to the full-length protein sequence of an invention Bcl-G. In certain embodiments, the amino acid lengths include, for example, at least about 10 amino acids, at least about 15, at least about 20, at least about 25, at least about 30, at least about 35, at least about 40, at least about 45, at least about 50, at least about 75, at least about 100, at least about 150, at least about 200, at least about 250 or more amino acids in length up to the full-length Bcl-G protein sequence. The functional fragments can be contiguous amino acid sequences of a Bcl-G polypeptide, including contiguous amino acid sequences of SEQ ID NOS:2, 4 or 42.

A modification of a polypeptide can also include derivatives, analogues and functional mimetics thereof, provided that such polypeptide displays the Bcl-G biological activity. For example, derivatives can include chemical modifications of the polypeptide such as alkylation, acylation, carbamylation, iodination, or any

modification that derivatizes the polypeptide. Such derivatized molecules include, for example, those molecules in which free amino groups have been derivatized to form amine hydrochlorides, p-toluene sulfonyl groups, carbobenzoxy groups, t-butyloxycarbonyl groups, chloroacetyl groups or formyl groups. Free carboxyl groups can be derivatized to form salts, methyl and ethyl esters or other types of esters or hydrazides. Free hydroxyl groups can be derivatized to form O-acyl or O-alkyl derivatives. The imidazole nitrogen of histidine can be derivatized to form N-im-benzylhistidine. Also included as derivatives or analogues are those peptides which contain one or more naturally occurring amino acid derivatives of the twenty standard amino acids, for example, 4-hydroxyproline, 5-hydroxylysine, 3-methylhistidine, homoserine, ornithine or carboxyglutamate, and can include amino acids that are not linked by peptide bonds. Polypeptides of the present invention also include any polypeptide having one or more additions and/or deletions of residues, relative to the sequence of a polypeptide whose sequence is shown herein, so long as Bcl-G activity is maintained.

A modification of a Bcl-G polypeptide includes functional mimetics thereof. Mimetics encompass chemicals containing chemical moieties that mimic the function of the polypeptide. For example, if a polypeptide contains two charged chemical moieties having functional activity, a mimetic places two charged chemical moieties in a spatial orientation and constrained structure so that the charged chemical function is maintained in three-dimensional space. Thus, a mimetic, which orients functional groups that provide a function of Bcl-G, are included within the meaning of a Bcl-G derivative. All of these modifications are

included within the term "polypeptide" so long as the Bcl-G polypeptide or functional fragment retains its function.

The invention provides an isolated Bcl-G polypeptide, or functional fragment thereof. The invention Bcl-G polypeptides can be isolated by a variety of methods well-known in the art, for example, recombinant expression systems described herein, precipitation, gel filtration, ion-exchange, reverse-phase and affinity chromatography, and the like. Other well-known methods are described in Deutscher et al., Guide to Protein Purification: Methods in Enzymology Vol. 182, (Academic Press, (1990)). Alternatively, the isolated polypeptides of the present invention can be obtained using well-known recombinant methods (see, for example, Sambrook et al., *supra*, 1989; Ausubel et al., *supra*, 1999). The methods and conditions for biochemical purification of a polypeptide of the invention can be chosen by those skilled in the art, and purification monitored, for example, by an immunological assay or a functional assay.

An example of the means for preparing the invention polypeptide(s) is to express nucleic acids encoding Bcl-G in a suitable host cell, such as a bacterial cell, a yeast cell, an amphibian cell such as an oocyte, or a mammalian cell, using methods well known in the art, and recovering the expressed polypeptide, again using well-known purification methods, so described herein. Invention polypeptides can be isolated directly from cells that have been transformed with expression vectors as described herein. Recombinantly expressed polypeptides of the invention can also be expressed as fusion proteins with appropriate affinity tags, such as

glutathione S transferase (GST) or poly His, and affinity purified. The invention polypeptide, biologically functional fragments, and functional equivalents thereof can also be produced by chemical synthesis. For example, 5 synthetic polypeptides can be produced using Applied Biosystems, Inc. Model 430A or 431A automatic peptide synthesizer (Foster City, CA) employing the chemistry provided by the manufacturer.

Bcl-G polypeptides can be administered to an individual to increase an activity associated with a Bcl-G polypeptide, including induction of apoptosis or functioning as a tumor suppressor. For example, a Bcl-G polypeptide can be administered therapeutically to an individual using expression vectors containing nucleic acids encoding Bcl-G polypeptides, as described below. 15 In addition, Bcl-G polypeptides, or a functional portion thereof, can be directly administered to an individual. Methods of administering therapeutic polypeptides are well known to those skilled in the art, for example, as a 20 pharmaceutical composition.

In a particular embodiment, a Bcl-G polypeptide, or functional fragment thereof, can be administered to an individual so that the Bcl-G polypeptide or functional fragment is targeted to a tumor to induce apoptosis or otherwise function as a tumor 25 suppressor. One method of delivering a Bcl-G polypeptide to an intracellular target is to fuse a Bcl-G polypeptide or functional fragment to an intracellular-targeting peptide that can penetrate the cell membrane or otherwise 30 deliver a polypeptide to the intracellular environment such as via internalization, thereby causing the fused Bcl-G polypeptide to enter the cell. One example of such an intracellular-targeting peptides is a fusion to the

transduction domain of HIV TAT, which allows transduction of up to 100% of cells (Schwarze et al., Science 285:1569-1572 (1999); Vocero-Akbani et al., Nature Med. 5:29-33 (1999)).

5                   Another example of such an intracellular-targeting peptide is the Antennapeida homeoprotein internalization domain (Holinger et al., J. Biol. Chem. 274:13298-13304 (1999)). Still another intracellular-targeting peptide is a peptide that is specific for a  
10 cell surface receptor, which allows binding and internalization of a fusion polypeptide via receptor-mediated endocytosis (Ellerby et al., Nature Med. 5:1032-1038 (1999)). Such intracellular-targeting peptides that mediate specific receptor interactions can be  
15 advantageously used to target a tumor (see Ellerby et al., *supra*, 1999). Alternatively, a Bcl-G polypeptide of the invention can be incorporated, if desired, into liposomes, microspheres or other polymer matrices (Gregoriadis, Liposome Technology, Vols. I to III,  
20 2nd ed., CRC Press, Boca Raton FL (1993)).

The invention additionally provides a method for modulating the activity of an oncogenic polypeptide by contacting the oncogenic polypeptide with a  
substantially pure Bcl-G, or an oncogenic protein-binding  
25 fragment thereof. Bcl-G can function to bind oncogenic proteins such as Bcl-2. Therefore, Bcl-G or functional fragments that bind to an oncogenic protein such as Bcl-2 can be used to modulate the activity of the oncogenic protein.

30                   The present invention also provides compositions containing an acceptable carrier and any of an isolated, purified Bcl-G mature protein or functional

polypeptide fragments thereof, alone or in combination with each other. These polypeptides or proteins can be recombinantly derived, chemically synthesized or purified from native sources. As used herein, the term

5 "acceptable carrier" encompasses any of the standard pharmaceutical carriers, such as phosphate buffered saline solution, water and emulsions such as an oil and water emulsion, and various types of wetting agents.

The invention thus provides a therapeutic

10 composition comprising a pharmaceutically acceptable carrier and a compound selected from the group consisting of a Bcl-G polypeptide, a functional fragment of Bcl-G, a Bcl-G modulating compound, and an anti-Bcl-G antibody. The invention additionally provides a method of treating

15 a pathology characterized by abnormal cell proliferation by administering an effective amount of the composition containing a pharmaceutically acceptable carrier and a compound selected from the group consisting of a Bcl-G polypeptide, a functional fragment of Bcl-G, a Bcl-G

20 modulating compound, and an anti-Bcl-G antibody.

Also provided are antisense-nucleic acids having a sequence capable of binding specifically with full-length or any portion of an mRNA that encodes Bcl-G polypeptides so as to prevent translation of the mRNA.

25 The antisense-nucleic acid can have a sequence capable of binding specifically with any portion of the sequence of the cDNA encoding Bcl-G polypeptides. As used herein, the phrase "binding specifically" encompasses the ability of a nucleic acid sequence to recognize a complementary

30 nucleic acid sequence and to form double-helical segments therewith via the formation of hydrogen bonds between the complementary base pairs. An example of an antisense-nucleic acid is an antisense-nucleic acid comprising



chemical analogs of nucleotides.

The present invention provides means to modulate levels of expression of Bcl-G polypeptides by recombinantly expressing Bcl-G anti-sense nucleic acids or employing synthetic anti-sense nucleic acid compositions (hereinafter SANC) that inhibit translation of mRNA encoding these polypeptides. Synthetic oligonucleotides, or other antisense-nucleic acid chemical structures designed to recognize and selectively bind to mRNA are constructed to be complementary to full-length or portions of an Bcl-G coding strand, including nucleotide sequences set forth in SEQ ID NOS:1, 3 or 41.

The SANC is designed to be stable in the blood stream for administration to a subject by injection, or in laboratory cell culture conditions. The SANC is designed to be capable of passing through the cell membrane in order to enter the cytoplasm of the cell by virtue of physical and chemical properties of the SANC, which render it capable of passing through cell membranes, for example, by designing small, hydrophobic SANC chemical structures, or by virtue of specific transport systems in the cell which recognize and transport the SANC into the cell. In addition, the SANC can be designed for administration only to certain selected cell populations by targeting the SANC to be recognized by specific cellular uptake mechanisms which bind and take up the SANC only within select cell populations. In a particular embodiment the SANC is an antisense oligonucleotide.

For example, the SANC may be designed to bind to a receptor found only in a certain cell type, as discussed above. The SANC is also designed to recognize

and selectively bind to target mRNA sequence, which can correspond to a sequence contained within the sequences shown in SEQ ID NOS:1, 3 or 41. The SANC is designed to inactivate target mRNA sequence by either binding thereto and inducing degradation of the mRNA by, for example, RNase I digestion, or inhibiting translation of mRNA target sequence by interfering with the binding of translation-regulating factors or ribosomes, or inclusion of other chemical structures, such as ribozyme sequences or reactive chemical groups which either degrade or chemically modify the target mRNA. SANCs have been shown to be capable of such properties when directed against mRNA targets (see Cohen et al., TIPS, 10:435 (1989) and Weintraub, Sci. American, January (1990), pp.40).

The invention further provides a method of modulating the level of apoptosis in a cell by introducing an antisense nucleotide sequence into the cell, wherein the antisense nucleotide sequence specifically hybridizes to a nucleic acid molecule encoding a Bcl-G, wherein the hybridization reduces or inhibits the expression of the Bcl-G in the cell. The use of anti-sense nucleic acids, including recombinant anti-sense nucleic acids or SANCs, can be advantageously used to inhibit cell death.

Compositions comprising an amount of the antisense-nucleic acid of the invention, effective to reduce expression of Bcl-G polypeptides by entering a cell and binding specifically to mRNA encoding Bcl-G polypeptides so as to prevent translation and an acceptable hydrophobic carrier capable of passing through a cell membrane are also provided herein. Suitable hydrophobic carriers are described, for example, in U.S. Patent Nos. 5,334,761; 4,889,953; 4,897,355, and the

like. The acceptable hydrophobic carrier capable of passing through cell membranes may also comprise a structure which binds to a receptor specific for a selected cell type and is thereby taken up by cells of the selected cell type. For example, the structure can be part of a protein known to bind to a cell-type specific receptor such as a tumor.

Antisense-nucleic acid compositions are useful to inhibit translation of mRNA encoding invention polypeptides. Synthetic oligonucleotides, or other antisense chemical structures are designed to bind to mRNA encoding Bcl-G polypeptides and inhibit translation of mRNA and are useful as compositions to inhibit expression of Bcl-G associated genes in a tissue sample or in a subject.

The invention also provides a method for expression of a Bcl-G polypeptide by culturing cells containing a Bcl-G nucleic acid under conditions suitable for expression of Bcl-G. Thus, there is provided a method for the recombinant production of a Bcl-G of the invention by expressing the nucleic acid sequences encoding Bcl-G in suitable host cells. Recombinant DNA expression systems that are suitable to produce Bcl-G described herein are well-known in the art (see, for example, Ausubel et al., *supra*, 1999). For example, the above-described nucleotide sequences can be incorporated into vectors for further manipulation. As used herein, vector refers to a recombinant DNA or RNA plasmid or virus containing discrete elements that are used to introduce heterologous DNA into cells for either expression or replication thereof.

The invention also provides vectors containing the Bcl-G nucleic acids of the invention. Suitable expression vectors are well-known in the art and include vectors capable of expressing nucleic acid operatively  
5 linked to a regulatory sequence or element such as a promoter region or enhancer region that is capable of regulating expression of such nucleic acid. Appropriate expression vectors include those that are replicable in eukaryotic cells and/or prokaryotic cells and those that  
10 remain episomal or those which integrate into the host cell genome.

Promoters or enhancers, depending upon the nature of the regulation, can be constitutive or regulated. The regulatory sequences or regulatory  
15 elements are operatively linked to a nucleic acid of the invention such that the physical and functional relationship between the nucleic acid and the regulatory sequence allows transcription of the nucleic acid.

Suitable vectors for expression in prokaryotic  
20 or eukaryotic cells are well known to those skilled in the art (see, for example, Ausubel et al., supra, 1999). Vectors useful for expression in eukaryotic cells can include, for example, regulatory elements including the SV40 early promoter, the cytomegalovirus (CMV) promoter,  
25 the mouse mammary tumor virus (MMTV) steroid-inducible promoter, Moloney murine leukemia virus (MMLV) promoter, and the like. The vectors of the invention are useful for subcloning and amplifying a Bcl-G nucleic acid molecule and for recombinantly expressing a Bcl-G  
30 polypeptide. A vector of the invention can include, for example, viral vectors such as a bacteriophage, a baculovirus or a retrovirus; cosmids or plasmids; and, particularly for cloning large nucleic acid molecules,

bacterial artificial chromosome vectors (BACs) and yeast artificial chromosome vectors (YACs). Such vectors are commercially available, and their uses are well known in the art. One skilled in the art will know or can readily determine an appropriate promoter for expression in a particular host cell.

The invention additionally provides recombinant cells containing Bcl-G nucleic acids of the invention. The recombinant cells are generated by introducing into a host cell a vector containing a Bcl-G nucleic acid molecule. The recombinant cells are transduced, transfected or otherwise genetically modified. Exemplary host cells that can be used to express recombinant Bcl-G molecules include mammalian primary cells; established mammalian cell lines, such as COS, CHO, HeLa, NIH3T3, HEK 293 and PC12 cells; amphibian cells, such as *Xenopus* embryos and oocytes; and other vertebrate cells. Exemplary host cells also include insect cells such as *Drosophila*, yeast cells such as *Saccharomyces cerevisiae*, *Saccharomyces pombe*, or *Pichia pastoris*, and prokaryotic cells such as *Escherichia coli*.

In one embodiment, nucleic acids encoding the invention Bcl-G polypeptides can be delivered into mammalian cells, either *in vivo* or *in vitro* using suitable vectors well-known in the art. Suitable vectors for delivering a Bcl-G polypeptide, or a functional fragment thereof to a mammalian cell, include viral vectors such as retroviral vectors, adenovirus, adeno-associated virus, lentivirus, herpesvirus, as well as non-viral vectors such as plasmid vectors. Such vectors are useful for providing therapeutic amounts of a Bcl-G polypeptide (see, for example, U.S. Patent No. 5,399,346, issued March 21, 1995). Delivery of Bcl-G polypeptides

or nucleic acids therapeutically can be particularly useful when targeted to a tumor cell, thereby inducing apoptosis in tumor cells. In addition, where it is desirable to limit or reduce the *in vivo* expression of the invention Bcl-G, the introduction of the antisense strand of the invention nucleic acid is contemplated.

Viral based systems provide the advantage of being able to introduce relatively high levels of the heterologous nucleic acid into a variety of cells. Suitable viral vectors for introducing invention nucleic acid encoding an Bcl-G protein into mammalian cells are well known in the art. These viral vectors include, for example, Herpes simplex virus vectors (Geller et al., Science, 241:1667-1669 (1988)); vaccinia virus vectors (Piccini et al., Meth. Enzymology, 153:545-563 (1987)); cytomegalovirus vectors (Mocarski et al., in Viral Vectors, Y. Gluzman and S.H. Hughes, Eds., Cold Spring Harbor Laboratory, Cold Spring Harbor, N.Y., 1988, pp. 78-84); Moloney murine leukemia virus vectors (Danos et al., Proc. Natl. Acad. Sci. USA, 85:6460-6464 (1988); Blaese et al., Science, 270:475-479 (1995); Onodera et al., J. Virol., 72:1769-1774 (1998)); adenovirus vectors (Berkner, Biotechniques, 6:616-626 (1988); Cotten et al., Proc. Natl. Acad. Sci. USA, 89:6094-6098 (1992); Graham et al., Meth. Mol. Biol., 7:109-127 (1991); Li et al., Human Gene Therapy, 4:403-409 (1993); Zabner et al., Nature Genetics, 6:75-83 (1994)); adeno-associated virus vectors (Goldman et al., Human Gene Therapy, 10:2261-2268 (1997); Greelish et al., Nature Med., 5:439-443 (1999); Wang et al., Proc. Natl. Acad. Sci. USA, 96:3906-3910 (1999); Snyder et al., Nature Med., 5:64-70 (1999); Herzog et al., Nature Med., 5:56-63 (1999)); retrovirus vectors (Donahue et al., Nature Med., 4:181-186 (1998); Shackelford et al., Proc. Natl. Acad. Sci. USA,

85:9655-9659 (1988); U.S. Patent Nos. 4,405,712,  
4,650,764 and 5,252,479, and WIPO publications WO  
92/07573, WO 90/06997, WO 89/05345, WO 92/05266 and WO  
92/14829; and lentivirus vectors (Kafri et al., Nature  
5 Genetics, 17:314-317 (1997)).

For example, in one embodiment of the present  
invention, adenovirus-transferrin/polylysine-DNA  
(TfAdpl-DNA) vector complexes (Wagner et al., Proc. Natl.  
Acad. Sci., USA, 89:6099-6103 (1992); Curiel et al., Hum.  
10 Gene Ther., 3:147-154 (1992); Gao et al., Hum. Gene  
Ther., 4:14-24 (1993)) are employed to transduce  
mammalian cells with heterologous Bcl-G nucleic acid.  
Any of the plasmid expression vectors described herein  
may be employed in a TfAdpl-DNA complex.

15 Vectors useful for therapeutic administration  
of a Bcl-G polypeptide or nucleic acid can contain a  
regulatory element that provides tissue specific or  
inducible expression of an operatively linked nucleic  
acid. One skilled in the art can readily determine an  
20 appropriate tissue-specific promotor or enhancer that  
allows exparssion of a Bcl-G polypeptide or nucleic acid  
in a desired tissue. Any of a variety of inducible  
promoters or enhancers can also be included in the vector  
for regulatable expression of a Bcl-G polypeptide or  
25 nucleic acid. Such inducible systems, include, for  
example, tetracycline inducible system (Gossen & Bizard,  
Proc. Natl. Acad. Sci. USA, 89:5547-5551 (1992); Gossen  
et al., Science, 268:1766-1769 (1995); Clontech, Palo  
Alto, CA); metalothionein promoter induced by heavy  
30 metals; insect steroid hormone responsive to ecdysone or  
related steroids such as muristerone (No et al., Proc.  
Natl. Acad. Sci. USA, 93:3346-3351 (1996); Yao et al.,  
Nature, 366:476-479 (1993); Invitrogen, Carlsbad, CA);

mouse mammary tumor virus (MMTV) induced by steroids such as glucocorticoid and estrogen (Lee et al., *Nature*, 294:228-232 (1981); and heat shock promoters inducible by temperature changes.

5                   An inducible system particularly useful for therapeutic administration utilizes an inducible promoter that can be regulated to deliver a level of therapeutic product in response to a given level of drug administered to an individual and to have little or no expression of  
10 the therapeutic product in the absence of the drug. One such system utilizes a Gal4 fusion that is inducible by an antiprogestin such as mifepristone in a modified adenovirus vector (Burien et al., *Proc. Natl. Acad. Sci. USA*, 96:355-360 (1999)). Another such inducible system  
15 utilizes the drug rapamycin to induce reconstitution of a transcriptional activator containing rapamycin binding domains of FKBP12 and FRAP in an adeno-associated virus vector (Ye et al., *Science*, 283:88-91 (1999)). It is understood that any combination of an inducible system  
20 can be combined in any suitable vector, including those disclosed herein. Such a regulatable inducible system is advantageous because the level of expression of the therapeutic product can be controlled by the amount of drug administered to the individual or, if desired,  
25 expression of the therapeutic product can be terminated by stopping administration of the drug.

                  The invention additionally provides an isolated anti-Bcl-G antibody having specific reactivity with a Bcl-G. The anti-Bcl-G antibody can be a monoclonal  
30 antibody or a polyclonal antibody. The invention further provides cell lines producing monoclonal antibodies having specific reactivity with a Bcl-G.



The invention thus provides antibodies that specifically bind a Bcl-G polypeptide. As used herein, the term "antibody" is used in its broadest sense to include polyclonal and monoclonal antibodies, as well as antigen binding fragments of such antibodies. With regard to an anti-Bcl-G antibody of the invention, the term "antigen" means a native or synthesized Bcl-G polypeptide or fragment thereof. An anti-Bcl-G antibody, or antigen binding fragment of such an antibody, is characterized by having specific binding activity for a Bcl-G polypeptide or a peptide portion thereof of at least about  $1 \times 10^5 \text{ M}^{-1}$ . Thus, Fab, F(ab')<sub>2</sub>, Fd and Fv fragments of an anti-Bcl-G antibody, which retain specific binding activity for a Bcl-G polypeptide, are included within the definition of an antibody. Specific binding activity of a Bcl-G polypeptide can be readily determined by one skilled in the art, for example, by comparing the binding activity of an anti-Bcl-G antibody to a Bcl-G polypeptide versus a control polypeptide that is not a Bcl-G polypeptide. Methods of preparing polyclonal or monoclonal antibodies are well known to those skilled in the art (see, for example, Harlow and Lane, Antibodies: A Laboratory Manual, Cold Spring Harbor Laboratory Press (1988)).

In addition, the term "antibody" as used herein includes naturally occurring antibodies as well as non-naturally occurring antibodies, including, for example, single chain antibodies, chimeric, bifunctional and humanized antibodies, as well as antigen-binding fragments thereof. Such non-naturally occurring antibodies can be constructed using solid phase peptide synthesis, can be produced recombinantly or can be obtained, for example, by screening combinatorial libraries consisting of variable heavy chains and

variable light chains as described by Huse et al. (Science 246:1275-1281 (1989)). These and other methods of making, for example, chimeric, humanized, CDR-grafted, single chain, and bifunctional antibodies are well known to those skilled in the art (Winter and Harris, Immunol. Today 14:243-246 (1993); Ward et al., Nature 341:544-546 (1989) ; Harlow and Lane, *supra*, 1988); Hilyard et al., Protein Engineering: A practical approach (IRL Press 1992); Borrabeck, Antibody Engineering, 2d ed. (Oxford University Press 1995)).

Anti-Bcl-G antibodies can be raised using a Bcl-G immunogen such as an isolated Bcl-G polypeptide having the amino acid sequence of SEQ ID NOS:2, 4 or 42, or a fragment thereof, which can be prepared from natural sources or produced recombinantly, or a peptide portion of the Bcl-G polypeptide. Such peptide portions of a Bcl-G polypeptide are functional antigenic fragments if the antigenic peptides can be used to generate a Bcl-G-specific antibody. A non-immunogenic or weakly immunogenic Bcl-G polypeptide or portion thereof can be made immunogenic by coupling the hapten to a carrier molecule such as bovine serum albumin (BSA) or keyhole limpet hemocyanin (KLH). Various other carrier molecules and methods for coupling a hapten to a carrier molecule are well known in the art (see, for example, Harlow and Lane, *supra*, 1988). An immunogenic Bcl-G polypeptide fragment can also be generated by expressing the peptide portion as a fusion protein, for example, to glutathione S transferase (GST), polyHis or the like. Methods for expressing peptide fusions are well known to those skilled in the art (Ausubel et al., Current Protocols in Molecular Biology (Supplement 47), John Wiley & Sons, New York (1999)).

The invention further provides a method for detecting the presence of a human Bcl-G in a sample by contacting a sample with a Bcl-G-specific antibody, and detecting the presence of specific binding of the antibody to the sample, thereby detecting the presence of a human Bcl-G in the sample. Bcl-G specific antibodies can be used in diagnostic methods and systems to detect the level of Bcl-G present in a sample. As used herein, the term "sample" is intended to mean any biological fluid, cell, tissue, organ or portion thereof, that includes or potentially includes Bcl-G nucleic acids or polypeptides. The term includes samples present in an individual as well as samples obtained or derived from the individual. For example, a sample can be a histologic section of a specimen obtained by biopsy, or cells that are placed in or adapted to tissue culture. A sample further can be a subcellular fraction or extract, or a crude or substantially pure nucleic acid or protein preparation.

Bcl-G-specific antibodies can also be used for the immunoaffinity or affinity chromatography purification of the invention Bcl-G. In addition, methods are contemplated herein for detecting the presence of an invention Bcl-G protein in a cell, comprising contacting the cell with an antibody that specifically binds to Bcl-G polypeptides under conditions permitting binding of the antibody to the Bcl-G polypeptides, detecting the presence of the antibody bound to the Bcl-G polypeptide, and thereby detecting the presence of invention polypeptides in a cell. With respect to the detection of such polypeptides, the antibodies can be used for *in vitro* diagnostic or *in vivo* imaging methods.

Immunological procedures useful for *in vitro* detection of target Bcl-G polypeptides in a sample include immunoassays that employ a detectable antibody. Such immunoassays include, for example, immunohistochemistry, immunofluorescence, ELISA assays, radioimmunoassay, FACS analysis, immunoprecipitation, immunoblot analysis, Pandex microfluorimetric assay, agglutination assays, flow cytometry and serum diagnostic assays, which are well known in the art (Harlow and Lane, *supra*, 1988; Harlow and Lane, Using Antibodies: A Laboratory Manual, Cold Spring Harbor Press (1999)).

An antibody can be made detectable by various means well known in the art. For example, a detectable marker can be directly attached to the antibody or indirectly attached using, for example, a secondary agent that recognizes the Bcl-G specific antibody. Useful markers include, for example, radionucleotides, enzymes, binding proteins such as biotin, fluorogens, chromogens and chemiluminescent labels.

As used herein, the terms "label" and "indicating means" in their various grammatical forms refer to single atoms and molecules that are either directly or indirectly involved in the production of a detectable signal. Any label or indicating means can be linked to invention nucleic acid probes, expressed proteins, polypeptide fragments, or antibody molecules. These atoms or molecules can be used alone or in conjunction with additional reagents. Such labels are themselves well-known in clinical diagnostic chemistry.

The labeling means can be a fluorescent labeling agent that chemically binds to antibodies or antigens without denaturation to form a fluorochrome

(dye) that is a useful immunofluorescent tracer. A description of immunofluorescent analytic techniques is found in DeLuca, "Immunofluorescence Analysis", in Antibody As a Tool, Marchalonis et al., eds., John Wiley & Sons, Ltd., pp. 189-231 (1982), which is incorporated herein by reference.

In one embodiment, the indicating group is an enzyme, such as horseradish peroxidase (HRP), glucose oxidase, and the like. In another embodiment, radioactive elements are employed labeling agents. The linking of a label to a substrate, i.e., labeling of nucleic acid probes, antibodies, polypeptides, and proteins, is well known in the art. For instance, an invention antibody can be labeled by metabolic incorporation of radiolabeled amino acids provided in the culture medium. See, for example, Galfre et al., Meth. Enzymol., 73:3-46 (1981). Conventional means of protein conjugation or coupling by activated functional groups are particularly applicable. See, for example, Aurameas et al., Scand. J. Immunol., Vol. 8, Suppl. 7:7-23 (1978), Rodwell et al., Biotech., 3:889-894 (1984), and U.S. Patent No. 4,493,795.

In addition to detecting the presence of a Bcl-G polypeptide, invention anti-Bcl-G antibodies are contemplated for use herein to modulate the activity of the Bcl-G polypeptide in living animals, in humans, or in biological tissues or fluids isolated therefrom. The term "modulate" refers to a compound's ability to increase the biological activity by functioning as an agonist or inhibit the biological activity by functioning as an antagonist of an invention Bcl-G polypeptide. Accordingly, compositions comprising a carrier and an amount of an antibody having specificity for Bcl-G

polypeptides effective to block naturally occurring ligands or other Bcl-G-binding proteins from binding to invention Bcl-G polypeptides are contemplated herein. For example, a monoclonal antibody directed to an epitope of an invention Bcl-G polypeptide, including an amino acid sequence set forth in SEQ ID NOS:2, 4 or 42, can be useful for this purpose.

The present invention further provides transgenic non-human mammals that are capable of expressing exogenous nucleic acids encoding Bcl-G polypeptides. As employed herein, the phrase "exogenous nucleic acid" refers to nucleic acid sequence which is not native to the host, or which is present in the host in other than its native environment, for example, as part of a genetically engineered DNA construct. In addition to naturally occurring levels of Bcl-G, a Bcl-G polypeptide of the invention can either be overexpressed or underexpressed in transgenic mammals, for example, underexpressed in a knock-out animal.

Also provided are transgenic non-human mammals capable of expressing nucleic acids encoding Bcl-G polypeptides so mutated as to be incapable of normal activity. Therefore, the transgenic non-human mammals do not express native Bcl-G or have reduced expression of native Bcl-G. The present invention also provides transgenic non-human mammals having a genome comprising antisense nucleic acids complementary to nucleic acids encoding Bcl-G polypeptides, placed so as to be transcribed into antisense mRNA complementary to mRNA encoding Bcl-G polypeptides, which hybridizes to the mRNA and, thereby, reduces the translation thereof. The nucleic acid can additionally comprise an inducible promoter and/or tissue specific regulatory elements, so

that expression can be induced, or restricted to specific cell types.

Animal model systems useful for elucidating the physiological and behavioral roles of Bcl-G polypeptides are also provided, and are produced by creating transgenic animals in which the expression of the Bcl-G polypeptide is altered using a variety of techniques. Examples of such techniques include the insertion of normal or mutant versions of nucleic acids encoding an Bcl-G polypeptide by microinjection, retroviral infection or other means well known to those skilled in the art, into appropriate fertilized embryos to produce a transgenic animal, see, for example, Hogan et al., Manipulating the Mouse Embryo: A Laboratory Manual (Cold Spring Harbor Laboratory, (1986)). Transgenic animal model systems are useful for *in vivo* screening of compounds for identification of specific ligands, such as agonists or antagonists, which activate or inhibit a biological activity.

Also contemplated herein, is the use of homologous recombination of mutant or normal versions of Bcl-G genes with the native gene locus in transgenic animals, to alter the regulation of expression or the structure of Bcl-G polypeptides by replacing the endogeneous gene with a recombinant or mutated Bcl-G gene. Methods for producing a transgenic non-human mammal including a gene knock-out non-human mammal, are well known to those skilled in the art (see, Capecchi et al., Science 244:1288 (1989); Zimmer et al., Nature 338:150 (1989); Shastry, Experientia, 51:1028-1039 (1995); Shastry, Mol. Cell. Biochem., 181:163-179 (1998); and U.S. Patent No. 5,616,491, issued April 1, 1997, No. 5,750,826, issued May 12, 1998, and No. 5,981,830, issued

November 9, 1999).

Invention nucleic acids, oligonucleotides, including antisense, vectors containing invention nucleic acids, transformed host cells, polypeptides and combinations thereof, as well as antibodies of the present invention, can be used to screen compounds to determine whether a compound functions as a potential agonist or antagonist of invention polypeptides. These screening assays provide information regarding the function and activity of invention polypeptides, which can lead to the identification and design of compounds that are capable of specific interaction with one or more types of polypeptides, peptides or proteins.

Thus, the invention provides methods for identifying compounds which bind to Bcl-G polypeptides. The invention proteins can be employed in a competitive binding assay. Such an assay can accommodate the rapid screening of a large number of compounds to determine which compounds, if any, are capable of binding to Bcl-G polypeptides. Subsequently, more detailed assays can be carried out with those compounds found to bind, to further determine whether such compounds act as modulators, agonists or antagonists of invention Bcl-G polypeptides. Compounds that bind to and/or modulate invention Bcl-G polypeptides can be used to treat a variety of pathologies mediated by invention Bcl-G polypeptides.

Various binding assays to identify cellular proteins that interact with protein binding domains are known in the art and include, for example, yeast two-hybrid screening assays (see, for example, U.S. Patent Nos. 5,283,173, 5,468,614 and 5,667,973; Ausubel



et al., *supra*, 1999; Luban et al., Curr. Opin. Biotechnol. 6:59-64 (1995)) and affinity column chromatography methods using cellular extracts. By synthesizing or expressing polypeptide fragments  
5 containing various Bcl-G sequences or deletions, the Bcl-G binding interface can be readily identified.

In another embodiment of the invention, there is provided a bioassay for identifying compounds which modulate the activity of invention Bcl-G polypeptides.  
10 According to this method, invention polypeptides are contacted with an "unknown" or test substance, for example, in the presence of a reporter gene construct responsive to a Bcl-G signaling pathway, the activity of the polypeptide is monitored subsequent to the contact  
15 with the "unknown" or test substance, and those substances which cause the reporter gene construct to be expressed are identified as functional ligands for Bcl-G polypeptides. Such reporter gene assays and systems are well known to those skilled in the art (Ausubel et al.,  
20 *supra*, 1999). In addition, a reporter gene construct can be generated using the promoter region of Bcl-G and screened for compounds that increase or decrease Bcl-G gene promoter activity. Such compounds can also be used to alter Bcl-G expression.

25 In accordance with another embodiment of the present invention, transformed host cells that recombinantly express invention polypeptides can be contacted with a test compound, and the modulating effect(s) thereof can then be evaluated by comparing the  
30 Bcl-G-mediated response, for example, via reporter gene expression in the presence and absence of test compound, or by comparing the response of test cells or control cells, to the presence of the compound.

As used herein, a compound or a signal that "modulates the activity" of invention polypeptides refers to a compound or a signal that alters the activity of Bcl-G polypeptides so that the activity of the invention polypeptide is different in the presence of the compound or signal than in the absence of the compound or signal. In particular, such compounds or signals include agonists and antagonists. An agonist encompasses a compound or a signal that activates Bcl-G protein expression or biological activity. Alternatively, an antagonist includes a compound or signal that interferes with Bcl-G expression or biological activity. Typically, the effect of an antagonist is observed as a blocking of agonist-induced protein activation. Antagonists include competitive and non-competitive antagonists.

Assays to identify compounds that modulate Bcl-G polypeptide expression can involve detecting a change in Bcl-G polypeptide abundance in response to contacting the cell with a compound that modulates Bcl-G activity. Assays for detecting changes in polypeptide expression include, for example, immunoassays with Bcl-G-specific Bcl-G antibodies, such as immunoblotting, immunofluorescence, immunohistochemistry and immunoprecipitation assays, as described above.

As understood by those of skill in the art, assay methods for identifying compounds that modulate Bcl-G activity generally require comparison to a control. One type of a "control" is a cell or culture that is treated substantially the same as the test cell or test culture exposed to the compound, with the distinction that the "control" cell or culture is not exposed to the compound. Another type of "control" cell or culture can be a cell or culture that is identical to the test cells,

with the exception that the "control" cells or culture do not express a Bcl-G polypeptide. Accordingly, the response of the transfected cell to a compound is compared to the response, or lack thereof, of the "control" cell or culture to the same compound under the same reaction conditions.

Methods for producing pluralities of compounds to use in screening for compounds that modulate the activity of a Bcl-G polypeptide, including chemical or biological molecules such as simple or complex organic molecules, metal-containing compounds, carbohydrates, peptides, proteins, peptidomimetics, glycoproteins, lipoproteins, nucleic acids, antibodies, and the like, are well known in the art and are described, for example, in Huse, U.S. Patent No. 5,264,563; Francis et al., Curr. Opin. Chem. Biol. 2:422-428 (1998); Tietze et al., Curr. Biol., 2:363-371 (1998); Sofia, Mol. Divers. 3:75-94 (1998); Eichler et al., Med. Res. Rev. 15:481-496 (1995); and the like. Libraries containing large numbers of natural and synthetic compounds also can be obtained from commercial sources. Combinatorial libraries of molecules can be prepared using well known combinatorial chemistry methods (Gordon et al., J. Med. Chem. 37: 1233-1251 (1994); Gordon et al., J. Med. Chem. 37: 1385-1401 (1994); Gordon et al., Acc. Chem. Res. 29:144-154 (1996); Wilson and Czarnik, eds., Combinatorial Chemistry: Synthesis and Application, John Wiley & Sons, New York (1997)).

Compounds that modulate Bcl-G activity can be screened by the methods disclosed herein to identify compounds that modulate any biological activity or function of Bcl-G. For example, compounds can be identified that alter the interaction of Bcl-G with Bcl-2

family members. Additionally, compounds can be identified that modulate ion channel activity associated with Bcl-G. The formation of ion channels by Bcl-2 family members is one mechanism of inducing apoptosis in cells (Reed, *supra*, 1998). Therefore, compounds that modulate ion channel activity of Bcl-G can be used to alter apoptosis, thereby increasing or decreasing apoptotic activity of Bcl-G.

Another assay for screening of compounds that modulates the activity of Bcl-G is based on altering the phenotype of yeast by expressing Bcl-G. For example, expression of Bax in yeast confers a lethal phenotype (Matsuyama et al., Mol. Cell. 1:327-336 (1998)). A yeast that expresses Bcl-G can have a similar phenotype as Bax since the biological activity of Bcl-G is similar to Bax (Example III). Accordingly, a yeast strain expressing Bcl-G that confers a lethal phenotype can be screened for compounds that prevent cell death. In one embodiment, expression of Bcl-G can be inducible (Tao et al., J. Biol. Chem. 273:23704-23708 (1998)), and the compounds can be screened when Bcl-G expression is induced. Bcl-G can also be co-expressed in yeast with other Bcl-2 family members having anti-apoptotic activity such as Bcl-2 or Bcl-X<sub>L</sub>. For example, co-expression of Bax with Bcl-2 or Bcl-X<sub>L</sub> suppressed the lethal activity of Bax (Tao et al., *supra*, 1998). Similarly, co-expression of Bcl-G with an anti-apoptotic Bcl-2 family member such as Bcl-2 or Bcl-X<sub>L</sub> can be used to screen for compounds that antagonize the activity of the anti-apoptotic Bcl-2 family members and restore a lethal phenotype. Such compounds can function to inhibit binding of Bcl-G to anti-apoptotic Bcl-2 family members such as Bcl-2 or Bcl-X<sub>L</sub>.

In yet another embodiment of the present invention, the activation of Bcl-G polypeptides can be modulated by contacting the polypeptides with an effective amount of at least one compound identified by the assays described herein. The invention also provides a method of identifying an effective agent that alters the association of a Bcl-G with a Bcl-G associated polypeptide (BAP). The method includes the steps of contacting the Bcl-G and the BAP polypeptide, under conditions that allow said Bcl-G and BAP polypeptide to associate, with a compound; and detecting the altered association of the Bcl-G and BAP polypeptide, thereby identifying a compound that is an effective agent for altering the association of Bcl-G with BAP. The compound can be, for example, a drug or polypeptide. A BAP can be, for example, Bcl-2 family member such as Bcl-2 or Bcl-X<sub>L</sub>.

As disclosed herein, Bcl-G is a new member of the Bcl-2 family that has pro-apoptotic activity (see Example III). Therefore, modulation of Bcl-G activity can be advantageously used to modulate the level of apoptosis in a cell. For example, increasing the activity of Bcl-G can be used to promote apoptosis in a cell. Bcl-G activity can be increased, for example, by increasing the level of a Bcl-G polypeptide or functional fragment thereof. Increased levels of a Bcl-G polypeptide can be accomplished, for example, by delivering to a cell a nucleic acid encoding Bcl-G and expressing a Bcl-G polypeptide recombinantly or by delivering a Bcl-G polypeptide or functional fragment thereof directly to a target by the methods disclosed herein. Additionally, Bcl-G activity can be increased by using a modulatory agent that functions as an agonist. Promoting apoptosis by increasing Bcl-G activity or

expression is useful, for example, in therapeutic applications such as the treatment of cancer.

As disclosed herein, decreases or loss of Bcl-G is associated with approximately 50% of prostate cancers, approximately 30% of ovarian cancers and approximately 30% of leukemias. Bcl-G can function as a tumor suppressor. Therefore, methods of administering a Bcl-G polypeptide either directly or using an encoded nucleic acid can be used to treat a cancer. Furthermore, many chemotherapeutic agents function through increasing apoptosis. Therefore, the invention additionally provides a method to enhance a chemotherapy by increasing Bcl-G activity or expression. Administering Bcl-G can thus be used to enhance the effect of standard chemotherapeutic agents.

Alternatively, modulation of Bcl-G activity can be advantageously used to decrease Bcl-G activity to decrease apoptosis. For example, Bcl-G activity or expression can be decreased by administering an anti-sense Bcl-G nucleic acid. In addition, an antagonist of Bcl-G activity can be identified by the methods disclosed herein and used to decrease Bcl-G activity. Decreasing Bcl-G activity can be used to inhibit apoptosis. Inhibiting apoptosis can be useful, for example, to treat disease ischemic. For example, decreasing Bcl-G activity with anti-sense nucleic acids or small molecule compounds can be used to treat stroke, heart attack, autoimmunity, trauma, neuron cell death, and inflammatory diseases, including Crohn's disease. For example, Bcl-G was identified in Crohn's disease patients (see Example I).

The invention further provides a method for modulating an activity mediated by a Bcl-G polypeptide by

contacting the Bcl-G polypeptide with an effective,  
modulating amount of an agent that modulates Bcl-G  
activity. The Bcl-G activity can be, for example,  
apoptosis-inducing activity, binding to Bcl-2, or tumor  
5 suppressor activity. The invention additionally provides  
a method of modulating the level of apoptosis in a cell.  
The method includes the steps of introducing a nucleic  
acid molecule encoding a Bcl-G into the cell; and  
expressing the Bcl-G in the cell, wherein the expression  
10 of the Bcl-G modulates apoptosis in the cell.

The invention further provides a method of  
modulating the level of apoptosis in a cell by contacting  
the cell with a compound that effectively alters the  
association of Bcl-G with a Bcl-G-associated-protein in  
15 the cell, or that effectively alters the activity of a  
Bcl-G in the cell. Additionally provided by the  
invention is a method of modulating interactions between  
Bcl-G and Bcl-2 by contacting a Bcl-G polypeptide with  
the agent that inhibits or alters interactions between  
20 Bcl-G and Bcl-2.

As disclosed herein, Bcl-G is located on  
chromosome 12 in a region deleted in various cancers,  
including leukemia, prostate and ovarian cancer (Example  
IV). Therefore, methods using Bcl-G nucleic acids or  
25 antibodies can be used as a diagnostic for predisposition  
or progression of cancer, for example, leukemia, prostate  
or ovarian cancer. Changes in Bcl-G expression or  
activity can be correlated with patient survival or  
response to therapy, and a correlation can be used to  
30 monitor cancer progression or response to therapy.

The invention further provides a method of  
diagnosing a pathology characterized by an increased or

decreased level of a Bcl-G in a subject. The method includes the steps of (a) obtaining a test sample from the subject; (b) contacting the sample with an agent that can bind the Bcl-G under suitable conditions, wherein the conditions allow specific binding of the agent to the Bcl-G; and (c) comparing the amount of the specific binding in the test sample with the amount of specific binding in a control sample, wherein an increased or decreased amount of the specific binding in the test sample as compared to the control sample is diagnostic of a pathology. The agent can be, for example, an anti-Bcl-G antibody, a Bcl-G-associated-protein (BAP), or a Bcl-G nucleic acid.

The invention also provides a method of diagnosing cancer or monitoring cancer therapy by contacting a test sample from a patient with a Bcl-G-specific antibody. The invention additionally provides a method of assessing prognosis of patients with cancer comprising contacting a test sample from a patient with a Bcl-G-specific antibody.

The invention additionally provides a method of diagnosing cancer or monitoring cancer therapy by contacting a test sample from a patient with a Bcl-G oligonucleotide. The invention further provides a method of assessing prognosis of patients with cancer by contacting a test sample from a patient with a Bcl-G oligonucleotide.

The methods of the invention for diagnosing cancer or monitoring cancer therapy using a Bcl-G-specific antibody or Bcl-G oligonucleotide or nucleic acid can be used, for example, to segregate patients into a high risk group or a low risk group for predicting risk



of metastasis or risk of failure to respond to therapy. Therefore, the methods of the invention can be advantageously used to determine the risk of metastasis in a cancer patient or as a prognostic indicator of survival in a cancer patient. One of ordinary skill in the art would appreciate that the prognostic indicators of survival for cancer patients suffering from stage I cancer can be different from those for cancer patients suffering from stage IV cancer. For example, prognosis for stage I cancer patients can be oriented toward the likelihood of continued growth and/or metastasis of the cancer, whereas prognosis for stage IV cancer patients can be oriented toward the likely effectiveness of therapeutic methods for treating the cancer.

Accordingly, the methods of the invention directed to measuring the level of or determining the presence of a Bcl-G polypeptide or encoding nucleic acid can be used advantageously as a prognostic indicator for the presence or progression of a cancer or response to therapy.

In accordance with another embodiment of the present invention, there are provided diagnostic systems, preferably in kit form, comprising at least one invention nucleic acid or antibody in a suitable packaging material. The diagnostic kits containing nucleic acids are derived from the Bcl-G-encoding nucleic acids described herein. In one embodiment, for example, the diagnostic nucleic acids are derived from any of SEQ ID NOS:1, 3 or 41 and can be oligonucleotides of the invention. Invention diagnostic systems are useful for assaying for the presence or absence of nucleic acid encoding Bcl-G in either genomic DNA or mRNA.

A suitable diagnostic system includes at least one invention nucleic acid or antibody, as a separately

packaged chemical reagent(s) in an amount sufficient for at least one assay. For a diagnostic kit containing nucleic acid of the invention, the kit will generally contain two or more nucleic acids. When the diagnostic kit is to be used in PCR, the kit will contain at least two oligonucleotides that can serve as primers for PCR. Those of skill in the art can readily incorporate invention nucleic probes and/or primers or invention antibodies into kit form in combination with appropriate buffers and solutions for the practice of the invention methods as described herein. A kit containing a Bcl-G antibody can contain a reaction cocktail that provides the proper conditions for performing an assay, for example, an ELISA or other immunoassay, for determining the level of expression of a Bcl-G polypeptide in a sample, and can contain control samples that contain known amounts of a Bcl-G polypeptide and, if desired, a second antibody specific for the anti-Bcl-G antibody.

The contents of the kit of the invention, for example, Bcl-G nucleic acids or antibodies, are contained in packaging material, preferably to provide a sterile, contaminant-free environment. In addition, the packaging material contains instructions indicating how the materials within the kit can be employed both to detect the presence or absence of a particular Bcl-G sequence or Bcl-G polypeptide or to diagnose the presence of, or a predisposition for a condition associated with the presence or absence of Bcl-G such as cancer. The instructions for use typically include a tangible expression describing the reagent concentration or at least one assay method parameter, such as the relative amounts of reagent and sample to be admixed, maintenance time periods for reagent/sample admixtures, temperature, buffer conditions, and the like.

It is understood that modifications which do not substantially affect the activity of the various embodiments of this invention are also provided within the definition of the invention provided herein.

5 Accordingly, the following examples are intended to illustrate but not limit the present invention.

#### EXAMPLE I

##### Molecular Cloning of Bcl-G

10 This example describes the cloning of Bcl-G, a homologue of Bcl-2.

To clone the full length Bcl-G gene, oligonucleotide primers were designed based a short EST (GenBank Accession No. AW000827) from colonic mucosa of 3 patients with Crohn's disease found by searching a  
15 database for sequences similar to the BH2 and BH3 domains of Bcl-2 family proteins. The primers used were Primer 1 (5'GTACTTGGTGCCAAAGCCCAGG-3'; SEQ ID NO:7) and Primer 2 (5'-GACATGATGTCTGGTGTAGTAGGCGAGG-3'; SEQ DI NO:8). The full length Bcl-G cDNA was cloned using SMART™RACE cDNA  
20 Amplification Kit (Clontech; Palo Alto CA) from human placental total RNA (Clontech) as template. The 5'-RACE products were sequenced with an automated sequencer.

Briefly, for cloning of Bcl-G cDNAs, TBLAST searches of the public databases using human Bcl-2 as a  
25 query sequence revealed a short EST (GenBank AW000827) from colonic mucosa of 3 patients with Crohn's disease which contains an open reading frame (ORF) encoding sequences similar to the BH2 domain of Bcl-2 family proteins. An oligonucleotide primer  
30 (5'-GTACTTGGTGCCAAAGCCCAGG-3'; SEQ ID NO:7) was designed complementary to the EST sequence and used for 5'-RACE,

employing the SMART™ RACE cDNA Amplification Kit (Clontech; Palo Alto CA) and human placental total RNA as template. The 5'-RACE products were subcloned into pCR2.1-TOPO vector using the TOPO™ TA Cloning kit (Invitrogen; Carlsbad CA), and their DNA sequence determined, revealing a complete open reading frame (ORF), with start codon within a favorable Kozak sequence context, preceded by a 5' -untranslated region (UTR) containing stop codons in all three reading-frames (submitted to Genbank). Two additional EST clones, AI478889 and AI240211, were identified by BLAST searches, corresponding to overlapping partial Bcl-G cDNAs which contained the 3' -UTR.

A short EST was identified during searches of the public databases, which when conceptually translated revealed a polypeptide sequence with similarity to the BH2 domain of Bcl-2 family proteins. Full-length cDNAs were obtained, revealing two potential transcripts containing open reading frames (ORF) for proteins of 327 and 252 amino-acids, respectively, which were termed Bcl-G<sub>L</sub> and Bcl-G<sub>S</sub> (Figure 5A). The predicted Bcl-G<sub>L</sub> and Bcl-G<sub>S</sub> proteins are identical for the first 226 amino acids, then diverge thereafter. Comparison of the predicted amino acid sequences of Bcl-G<sub>L</sub> and Bcl-G<sub>S</sub> with Bcl-2 family proteins revealed the presence of a candidate BH3 domain (SEQ ID NO:9) in both Bcl-G<sub>L</sub> and Bcl-G<sub>S</sub> (Figure 5A,B), and the presence of a BH2 domain (SEQ ID NO:18) in Bcl-G<sub>L</sub> but not in Bcl-G<sub>S</sub> (Figure 5A, C).

Invention Bcl-G was found to exist in two forms, a long form, designated Bcl-G<sub>L</sub>, and a shorter form, designated Bcl-G<sub>S</sub>. The nucleotide sequence of Bcl-G<sub>L</sub> is shown in Figure 1 (SEQ ID NO:1). The nucleotide sequence of the coding region of Bcl-G<sub>L</sub> cDNA and the encoded amino

acid sequence (SEQ ID NO:3) are shown in Figure 2. Bcl-G<sub>L</sub> was initially identified to contain a core BH3 domain (<sup>216</sup>LKYSGDQLE<sup>224</sup>; SEQ ID NO:5) and a core BH2 domain (<sup>307</sup>PWIQQHGGWE<sup>316</sup>; SEQ ID NO:6).

5                   The shorter form of Bcl-G, Bcl-G<sub>S</sub>, is an apparent alternative splicing product of Bcl-G mRNA. The nucleotide sequence of Bcl-G<sub>S</sub> is shown in Figure 3 (SEQ ID NO:3). The nucleotide sequence of the coding region of Bcl-G<sub>S</sub> cDNA and the encoded amino acid sequence (SEQ ID  
10 NO:4) are shown in Figure 2. Bcl-G<sub>S</sub> contains only the BH3 domain (<sup>216</sup>LKYSGDQLE<sup>224</sup>).

                  These results demonstrate that a new member of the Bcl-2 family, Bcl-G, is expressed in human placenta and in the colonic mucosa of patients with Crohn's  
15 disease. Bcl-G exists in two forms, a long form, designated Bcl-G<sub>L</sub>, which contains a BH2 and BH3 domain, and a short form, designated Bcl-G<sub>S</sub>, which contains only a BH3 domain.

## EXAMPLE II

### 20                   **Mapping of Bcl-G to Chromosome 12p12.3**

                  This experiment describes chromosomal mapping of human Bcl-G.

                  To map the chromosomal location of Bcl-G, a search of the GenBank database was performed using BLAST  
25 (Altschul et al., J. Mol. Biol. 215:403-410 (1990); Altschul et al., Nucleic Acids Res. 25:3389-3402 (1997)). A 190858 bp human 12p12 BAC chromosome sequence RPCI11-267J23 (GenBank accession no. AC007537) was found to contain the full length Bcl-G gene. The BAC also  
30 contains the LRP6 gene (exon 1 starts at 89963 bp). A

600 kb region between 12p12.3 to 12p13.1, flanked by D12S358 and ETV6/exon8, was previously defined to be frequently deleted in childhood acute lymphoblastic leukemia (ALL) and other solid tumor cells (Baens et al., (1999) Genomics 56:40-50 (1999); Hatta et al., Br. J. Cancer 75:1256-1262 (1997); Kibel et al., Cancer Res. 58:5652-5655 (1998); Baccichet et al., Br. J. Haematol. 99:107-114 (1997); Aissani et al., Leuk. Lymphoma 34:231-239). The loss of the region containing Bcl-G occurs in approximately 50% of prostate cancers, 30% of ovarian cancers, and 30% of leukemias.

The LRP6 gene is located in the region between 12p12.3 to 12p13.1. Using LRP6 as a marker for orientation, Bcl-G was located in this region. Exon 1 of Bcl-G starts at 40674 bp in the BAC and was deduced from novel DNA sequence data obtained from 5' RACE-based amplification of the full-length Bcl-G cDNA. The genomic structure of the Bcl-G gene is shown in Figure 5. Bcl-G<sub>L</sub> has 6 exons, with the first codon non-coding, spreading across a 30 kb region in chromosome 12. Bcl-G<sub>S</sub> also has 6 exons, but a 153 bps sequence is inserted in front of exon 5 and contains a stop codon. The BH3 domain is located in exon 4 of both Bcl-G<sub>L</sub> and Bcl-G<sub>S</sub>. The BH2 domain is located in exon 5 of Bcl-G<sub>L</sub>. The Bcl-G<sub>L</sub> and Bcl-G<sub>S</sub> cDNAs can be accounted for by an alternative mRNA splicing mechanism in which different splice acceptor sites associated with exon 5 are employed, resulting in a change in the distal reading-frame (Figure 5D).

The chromosomal mapping of Bcl-G to chromosome 12p12.3 is shown in Figure 6. Bcl-G is located in a 600 kb region that has been previously determined to be frequently deleted in childhood ALL and other solid tumors (Baens et al., *supra*, 1999). Therefore, Bcl-G is

located in a region deleted in ALL and can function as a tumor suppressor or as a marker for tumor suppressor activity.

### Example III

5

#### Expression of Bcl-G

This example describes the expression of Bcl-G.

For generation of plasmids, cDNAs containing the ORFs of Bcl-G<sub>L</sub> and Bcl-G<sub>S</sub> without additional flanking sequences were generated by PCR using human placental cDNA as a template and the following primers:

10

5'-GGCTCGAGCGATGTGTAGCACCAGTGGGTGTGACC-3' (SEQ ID NO:27), sense for both Bcl-G<sub>L</sub> and Bcl-G<sub>S</sub>;

5'-CCAAGCTTTAAGTCTACTTCTTCATGTGATATCCC-3' (SEQ ID NO:28), antisense for Bcl-G<sub>L</sub>; and

15

5'-CCAAGCTTTAAAATGCAGGCCATCAAACC-3' (SEQ ID NO:29), antisense for Bcl-G<sub>S</sub>. The resulting PCR products were digested with restriction endonucleases and subcloned into the Xho I and Hind III sites of pEGFP-C1 (Clontech).

20

A mutant of Bcl-G<sub>S</sub> lacking the BH3 domain was created by a two-step PCR method, using the following primers:

primer1, 5'-GGCTCGAGCGATGTGTAGCACCAGTGGGTGTGACC-3' (SEQ ID NO:30); primer2,

5'-CCGGATCCGGCTAGTATTTGTTCTTCTTCATCTTTC-3' (SEQ ID NO:31); primer3, 5'-CCGGATCCGACACTGCCTTCATCCCCATTTCC-3'

25

(SEQ ID NO:32); and primer4, 5'-CCAAGCTTTAAAATGCAGGCCATCAAACC-3' (SEQ ID NO:33). The resulting PCR product was digested with XhoI / BamHI or with BamHI / HindIII respectively, and ligated into pEGFP-C1. Site-directed mutagenesis of Bcl-G<sub>S</sub> was

30

performed to generate a L216E substitution mutation using the QuikChange™ Site-Directed Mutagenesis Kit (Stratagene) following manufacturer's procedure, with

pEGFP-C1/Bcl-G<sub>s</sub> plasmid as DNA template, and the mutagenic primers: 5'-GCCAAAATTGTTGAGCTGGAGAAATATTCAGGAGATCAGTTGG-3' (SEQ ID NO:34) and 5'-CCAACTGATCTCCTGAATATTTCTCCAGCTCAACAATTTTGGC-3' (SEQ ID NO:35).

For measurements of Bcl-G mRNAs, Bcl-G mRNAs were detected by either Northern blotting or Reverse-Transcriptase-Polymerase Chain Reaction (RT-PCR). For RT-PCR, multiple-tissue cDNA panels (Clontech) containing first-strand cDNA generated from 16 different tissues were employed. PCR was performed according to the manufacturer's protocol with following primers: (a) 5' primer for both Bcl-G<sub>s</sub> and Bcl-G<sub>L</sub>, corresponding to exon 3, 5'-CTGAGGGTCTCTCCTTCCAGCTCCAAGG-3' (SEQ ID NO:36); (b) 3' primer for Bcl-G<sub>L</sub>, corresponding to exon 5, 5'-GGCCGTGACGTCTATTACAAGGGCAGCC-3' (SEQ ID NO:37); and 3' primer for Bcl-G<sub>s</sub>, corresponding to an alternatively spliced segment of exon 5, 5'-CAAGGGAATGGGGATGAAGGCAGTGTC-3' (SEQ ID NO:38). Human G3PDH expression was examined by PCR with the following primers: 5'-TGAAGGTCGGAGTCAACGGATTTGGT-3' (SEQ ID NO:39) (sense); and 5'-CATGTGGGCCATGAGGTCCACCAC-3' (SEQ ID NO:40) (antisense).

For tissue-specific expression of Bcl-G<sub>L</sub> and Bcl-G<sub>s</sub> mRNAs, Northern blotting demonstrated the presence of ~2 kbp Bcl-G transcripts in several normal human tissues, but failed to resolve the mRNAs encoding Bcl-G<sub>L</sub> and Bcl-G<sub>s</sub>. RT-PCR assays were therefore designed using primers specific for Bcl-G<sub>L</sub> and Bcl-G<sub>s</sub> sequences associated with exon 5. Bcl-G<sub>L</sub> mRNA was clearly detected in lung, pancreas, prostate and testis, with lower levels present in some other tissues (Figure 7). In contrast, Bcl-G<sub>s</sub> mRNA was uniquely expressed in testis. RT-PCR



amplification of a control mRNA, G3PDH, demonstrated loading of nearly equivalent amounts of mRNA from each tissue. The amplified bands corresponding to Bcl-G<sub>L</sub> and Bcl-G<sub>S</sub> were excised and sequenced, confirming the validity of the RT-PCR strategy.

#### EXAMPLE IV

##### Induction of Cell Death by Bcl-G<sub>S</sub>

This experiment describes the induction of cell death by Bcl-G<sub>S</sub> in transfected PC-3 cells.

For cell culture, transfections, and apoptosis assay, 293T and Cos-7 cells were cultured in DMEM high glucose media (Irvine Scientific, Santa Ana, CA) containing 10% fetal bovine serum (FBS). PC-3 cells were cultured with RPMI 1640 media containing 10% FBS. Transfection of cells was performed using SuperFect (Qiagen, Chatsworth, CA). Both floating and adherent cells (after trypsinization) were collected 24 hrs after transfection, fixed, and stained using 4',6-diamidino-2'-phenylindole dihydrochloride (DAPI) for assessing apoptosis based on nuclear fragmentation and chromatin condensation (Xu & Reed, Mol. Cell, 1:337-346 (1998); Zhang et al., Proc. Natl. Acad. Sci. (USA), 97:2597-2602 (2000)).

To characterize a biological function of Bcl-G, a Bcl-G<sub>S</sub> construct was generated by cloning Bcl-G<sub>S</sub> cDNA into pcDNA3.1/Myc/His expression vector (Invitrogen; Carlsbad CA) at the Xho I / Hind III sites. The authenticity of the construct was confirmed by DNA sequencing.

For transfection experiments, various vectors were transfected into PC-3 cells: control vector pcDNA3.1/Myc/His; pcDNA3.1/Myc/His/Bcl-G<sub>s</sub> expressing Bcl-G<sub>s</sub>; pRC/CMV/Bcl-2 expressing Bcl-2; and pRC/CMV/Bax expressing Bax. The vectors were transfected as follows: pcDNA3.1/Myc/His alone; pcDNA3.1/Myc/His/Bcl-G<sub>s</sub> alone; pcDNA3.1/Myc/His/Bcl-G<sub>s</sub> + pRC/CMV/Bcl-2; pRC/CMV/Bax alone; or pRC/CMV/Bax + pRC/CMV/Bcl-2. One µg of each vector was combined with 0.2 µg pEGFP-N2 (Clontech), and the vectors were transiently transfected into PC-3 prostate cancer cells using SuperFect reagent (QIAGEN; Valencia CA), following the instructions of the manufacturer. At 24 hours after transfection, cells were examined under a fluorescent microscope. About 100 green fluorescent protein (GFP) positive (green color) cells were counted for each transfection. Cells that were detached with membrane blebbing and/or apoptotic bodies were recorded as dead cells. Results were averaged from three separate transfections.

As shown in Figure 8, Bcl-G<sub>s</sub> induces cell death in PC-3 cells (compare "control" to "Bcl-G<sub>s</sub>"). The induction of cell death by Bcl-G<sub>s</sub> was similar to Bax, which was used as a positive control based on its known pro-apoptotic activity (compare "Bcl-G<sub>s</sub>" to "Bax"). The induction of cell death by Bcl-G<sub>s</sub> was completely inhibited when co-transfected with the anti-apoptotic Bcl-2 (see "Bcl-G<sub>s</sub> + Bcl-2"). The inhibition of Bcl-G<sub>s</sub>-induced cell death by Bcl-2 was similar to that seen with Bax (see "Bax + Bcl-2").

To assess the effects of Bcl-G<sub>L</sub> and further assess the effects of Bcl-G<sub>s</sub> on apoptosis, various cell lines, including Cos7, HEK293T, and PC3, were transiently transfected with plasmids encoding Bcl-G<sub>L</sub> or Bcl-G<sub>s</sub>. For

most experiments, Bcl-G<sub>L</sub> and Bcl-G<sub>S</sub> were expressed as GFP-fusions so that successfully transfected cells could be conveniently identified (Figure 9A), but similar results were obtained when Flag-epitope tags were employed instead. Over-expression of the shorter Bcl-G<sub>S</sub> protein reproducibly induced striking increases in the percentage of cells undergoing apoptosis, as determined by DAPI staining (Figure 9) and other methods. In contrast, Bcl-G<sub>L</sub> was more variable and less efficient at inducing apoptosis in these transient transfection assays. Immunoblot analysis of lysates from transfected cells demonstrated that the less potent effects of Bcl-G<sub>L</sub> could not be accounted for by lower levels of protein production (Figure 9A). Indeed, Bcl-G<sub>L</sub> protein accumulated to levels ~10-fold higher in cells compared to Bcl-G<sub>S</sub>, suggesting that Bcl-G<sub>S</sub> is a far more potent apoptosis-inducer. Analysis of the same blots with an anti-tubulin antibody confirm loading of essentially equivalent amounts of total protein for each sample, thus validating the results. In additional transfection experiments, Bcl-G<sub>L</sub> failed to demonstrate cytoprotective activity in side by side comparisons with Bcl-2 and Bcl-X<sub>L</sub>.

#### EXAMPLE V

#### **The BH3 Domain of Bcl-G<sub>S</sub> is Required for its Pro-apoptotic Activity**

The Bcl-G<sub>S</sub> protein contains a BH3 domain, but lacks other regions of homology with Bcl-2 family proteins. Structural studies indicate that BH3 domains represent amphipathic  $\alpha$ -helices, in which the hydrophobic surface of the  $\alpha$ -helices of apoptosis-inducing BH3 peptides bind to a pocket on survival proteins such as Bcl-X<sub>L</sub> (Sattler et al., *Science*, 275:983-986 (1997)).

Therefore, the apoptosis-inducing activity of the wild-type Bcl-G<sub>s</sub> protein was compared with mutants lacking the BH3 domain ( $\Delta$ BH3) or in which leucine 216 within the BH3 domain of Bcl-G<sub>s</sub> was chosen for mutation to charged glutamic acid, based on comparisons with previously described BH3 mutagenesis experiments demonstrating a critical requirement for the analogous leucine in other pro-apoptotic Bcl-2 family proteins (Wang et al., Mol. Cell. Biol., 18:6083-6089 (1998); Kelekar et al., Mol. Cell. Biol., 17:7040-7046 (1997)).

Wild-type Bcl-G<sub>s</sub> potently induced apoptosis when overexpressed in Cos-7, PC3, HEK293T and other cell lines, whereas Bcl-G<sub>s</sub> ( $\Delta$ BH3) and Bcl-G<sub>s</sub> (L216E) did not (see Figure 3B). Immunoblot analysis confirmed production of the Bcl-G<sub>s</sub> ( $\Delta$ BH3) and Bcl-G<sub>s</sub> (L216E) proteins at levels exceeding the amounts of wild-type Bcl-G<sub>s</sub> protein. Therefore, the BH3 domain of Bcl-G<sub>s</sub> is critical for its pro-apoptotic activity.

#### EXAMPLE VI

##### **Bcl-G<sub>s</sub> Associates with Bcl-X<sub>L</sub> in a BH3-dependent Manner**

The pro-apoptotic activity of "BH3-only" members of the Bcl-2 family depends on their ability to dimerize with and suppress the activity of survival proteins such as Bcl-X<sub>L</sub> (reviewed in Kelekar & Thompson, Trends Cell Biol., 8:324-330 (1998)). It was, therefore, determined whether Bcl-G<sub>L</sub> and Bcl-G<sub>s</sub> are capable of associating with other Bcl-2 family proteins by co-immunoprecipitation assays.

For co-immunoprecipitations and immunoblotting, immunoblotting was performed as described previously (Xu and Reed, supra., (1998); Zhang et al., supra., (2000)).

For co-immunoprecipitations, cells were cultured in 50 mM benzocarbonyl Valine Alanine Aspartate fluoromethylketone (zVAD-fmk) to prevent apoptosis. Cells were suspended in lysis buffer (50 mM Tris-HCl, pH7.4; 150 mM NaCl; 20 mM EDTA; 50 mM NaF; 0.5% NP-40; 0.1 mM Na<sub>3</sub>VO<sub>4</sub>; 20 µg/ml Leupeptin; 20 µg/ml Aprotinin; 1 mM dithiothreitol (DTT); and 1 mM phenylmethylsulfonylfluoride (PMSF). Lysates (0.2 ml diluted into 1 ml final volume of lysis buffer) were cleared by incubation with 15 µl of protein G-Sepharose 4B (Zymed; South San Francisco CA) and then incubated with 15 µl of polyclonal anti-GFP antibody (Santa Cruz; Santa Cruz CA) and 15 µl of protein G at 4°C overnight. Beads were then washed 4 times with 1.5 mls lysis buffer before boiling in Laemmli sample buffer and performing SDS-PAGE/immunoblotting.

Bcl-G<sub>s</sub> association with the survival proteins Bcl-X<sub>L</sub> and Bcl-2 was readily detected by co-immunoprecipitation using lysates from transiently transfected cells, whereas no association with pro-apoptotic proteins Bax, Bak, Bid or Bad was observed (Figure 10A). Interaction of Bcl-G<sub>s</sub> with Bcl-2 and Bcl-X<sub>L</sub>, but not with Bax or Bak, was also confirmed by yeast two-hybrid assays. In contrast, association of the longer Bcl-G<sub>L</sub> protein with Bcl-2 or Bcl-X<sub>L</sub> was not easily detected by co-immunoprecipitation assays (Figure 10A). With much longer x-ray film exposure times, however, small amounts of Bcl-X<sub>L</sub> were observed in association with Bcl-G<sub>L</sub> immunocomplexes, suggesting either low affinity binding of Bcl-G<sub>L</sub> to Bcl-X<sub>L</sub> or implying that only a small portion of total Bcl-G<sub>L</sub> proteins are competent to bind Bcl-X<sub>L</sub>. The interaction of Bcl-G<sub>s</sub> with Bcl-X<sub>L</sub> was BH3-dependent, as determined by comparisons of wild-type Bcl-G<sub>s</sub> with the Bcl-G<sub>s</sub> (ΔBH3) and Bcl-G<sub>s</sub> (L216E) proteins (Figures 10B, C). Thus, the pro-apoptotic activity of

Bcl-G<sub>s</sub> correlates with its ability to bind Bcl-X<sub>L</sub>.

#### EXAMPLE VII

##### Bcl-G<sub>s</sub> is Associated with Cytosolic Organelles

Many Bcl-2 family proteins, such as Bcl-2,  
5 Bcl-X<sub>L</sub>, and Bak, contain a hydrophobic stretch of amino-  
acids near their carboxyl-terminus that anchors them in  
intracellular membranes of mitochondria, endoplasmic  
reticulum, or nuclear envelope (reviewed in Reed, J. C.,  
Nature, 387:773-776 (1997); Adams & Cory, Science,  
10 281:1322-1326 (1998); Gross et al., Genes Dev., 13:1899-  
1911 (1999)). However, some pro-apoptotic Bcl-2 family  
proteins, such as Bax, Bid, and Bim, are found in the  
cytosol and must be induced to translocate to  
mitochondria and other organelles where the Bcl-2-family  
15 proteins to which they dimerize reside (Wolter et al., J.  
Cell Biol., 139:1281-1292 (1997); Puthalakath et al.,  
Mol. Cell, 3:287-96 (1999); Li et al., Cell, 94:491-501  
(1998); Luo et al., Cell, 94:481-490 (1998)).

The intracellular locations of the Bcl-G<sub>L</sub> and  
20 Bcl-G<sub>s</sub> protein was examined by confocal microscopy  
analysis of cells expressing GFP-tagged proteins.  
GFP-expressing cells were imaged by confocal microscopy  
using a Bio-Rad MRC 1024 instrument (Xu & Reed, supra.  
(1998); Zhang et al., supra. (2000); Zha et al., Mol.  
25 Cell. Biol., 16:6494-6508 (1996)). GFP-Bcl-G<sub>L</sub> protein was  
located diffusely throughout cells, similar to GFP  
control protein (Figure 11A, B). In contrast, Bcl-G<sub>s</sub> was  
found in a punctate cytosolic pattern (Figure 11C),  
suggestive of organelle association. Surprisingly,  
30 deletion of the BH3 domain from Bcl-G<sub>s</sub> did not disrupt the  
punctate distribution (Figure 5D), indicating that other  
regions of the Bcl-G<sub>s</sub> protein are sufficient for

subcellular targeting. Subcellular fractionation experiments confirmed these observations, demonstrating association of Bcl-G<sub>s</sub> and Bcl-G<sub>s</sub> (DB43) predominantly with organelle-containing heavy-membrane fractions, with scant amounts in the soluble cytosolic compartment.

#### **EXAMPLE VIII**

##### **Loss of Heterozygosity (LOH) is Associated with Bcl-G in Ovarian Tissue**

This example describes loss of heterozygosity (LOH) associated with Bcl-G in ovarian cancer tissue.

Ovarian cancer tissue samples were tested for SSCP for possible mutations in Bcl-G. No mutation was found in exon 1. However, about one third of the ovarian samples showed a possible LOH of Bcl-G. The LOH was observed as a change in band intensity using SSCP. The results were confirmed independently using PCR. The LOH samples are sequenced to determine specific mutations.

These results indicate that LOH is associated with Bcl-G in ovarian tissue and can be useful as a marker for ovarian cancer.

#### **Example IX**

##### **Cloning of Mouse Bcl-G**

This example describes cloning of mouse Bcl-G.

The mouse Bcl-G was identified by searching GenBank. An EST clone (AA536718) was found to contain mouse Bcl-G. The EST was purchased from the American Type Culture Collection (ATCC; Manassas VA) and sequenced

to determine the complete sequence of mouse Bcl-G.

The nucleotide sequence of mouse Bcl-G cDNA is referenced as SEQ ID NO:41. The amino acid sequence of Bcl-G is referenced as SEQ ID NO:42.

5 PCR was used to isolate mouse Bcl-G from the  
purchased EST clone and clone it into EGFP-C1 vector. he  
primers used were MXSTA,  
5'-GGGCTCGAGATGTGCAGCACCCAGTGTGTATG-3' (SEQ ID NO:43);  
NHREV, 5'-CCAAGCTTTAAGTCTACTTCTTCATGTGATATCCC-3' (SEQ ID  
10 NO:44).

In preliminary experiments, mouse Bcl-G was overexpressed in Cos-7 and 293T cells. In these preliminary experiments, apoptosis was not observed.

15 Throughout this application various  
publications have been referenced. The disclosures of  
these publications in their entireties are hereby  
incorporated by reference in this application in order to  
more fully describe the state of the art to which this  
invention pertains.

20 Although the invention has been described with  
reference to the examples provided above, it should be  
understood that various modifications can be made without  
departing from the spirit of the invention. Accordingly,  
the invention is limited only by the claims.



What is claimed is:

1. An isolated nucleic acid encoding a Bcl-G polypeptide, or a functional fragment thereof.

2. An isolated nucleic acid encoding a Bcl-G polypeptide, or a functional fragment thereof, comprising a nucleic acid selected from:

(a) nucleic acid encoding the amino acid sequence set forth in SEQ ID NOS:2, 4 or 42, or

(b) nucleic acid that hybridizes to the nucleic acid of (a) under moderately stringent conditions, wherein said nucleic acid contiguously encodes biologically active Bcl-G, or

(c) nucleic acid degenerate with respect to either (a) or (b) above, wherein said nucleic acid encodes biologically active Bcl-G.

3. The nucleic acid of claim 2, wherein said nucleic acid hybridizes under high stringency conditions to the Bcl-G coding portion of any of SEQ ID NOS:1, 3 or 41.

4. The nucleic acid of claim 2, wherein the nucleotide sequence of said nucleic acid is substantially the same as set forth in any of SEQ ID NOS:1, 3 or 41.

5. The nucleic acid of claim 2, wherein the nucleotide sequence of said nucleic acid is the same as that set forth in any of SEQ ID NOS:1, 3 or 41, or a modification thereof.

6. The nucleic acid of claim 2, wherein said nucleic acid is cDNA.

5 7. A vector containing the nucleic acid of claim 2.

8. Recombinant cells containing the nucleic acid of claim 2.

10 9. A Bcl-G oligonucleotide, comprising between 15 and 300 contiguous nucleotides of SEQ ID NOS:1, 3 or 41 or the anti-sense strand thereof.

10. An oligonucleotide according to claim 9, wherein said oligonucleotide is labeled with a detectable marker.

15 11. An antisense-nucleic acid capable of specifically binding to mRNA encoded by said nucleic acid according to claim 2.

12. A kit for detecting the presence of a Bcl-G nucleic acid sequence comprising at least one oligonucleotide according to claim 10.

20 13. An isolated Bcl-G polypeptide, or a functional fragment thereof, encoded by the nucleic acid of claim 2.

25 14. The Bcl-G polypeptide of claim 13, wherein said polypeptide comprises the substantially the same amino acid sequence of Bcl-G<sub>L</sub> (SEQ ID NO:2), Bcl-G<sub>S</sub> (SEQ ID NO:4), or mouse Bcl-G (SEQ ID NO:42).

15. The Bcl-G polypeptide of claim 14, wherein said polypeptide comprises the amino acid sequence of Bcl-G<sub>L</sub> (SEQ ID NO:2), Bcl-G<sub>S</sub> (SEQ ID NO:4), or mouse Bcl-G (SEQ ID NO:42).

5 16. The Bcl-G polypeptide of claim 13, wherein said functional fragment comprises a BH3 or BH2 domain.

10 17. The Bcl-G polypeptide of claim 16, wherein said functional fragment comprises an amino acid sequence selected from the group consisting of SEQ ID NOS:5, 6, 9 and 18.

18. The Bcl-G polypeptide of claim 13, wherein said polypeptide is encoded by a nucleotide sequence comprising substantially the same nucleotide sequence as set forth in SEQ ID NOS:1, 3 or 41.

15 19. The Bcl-G polypeptide of claim 13, wherein said polypeptide is encoded by a nucleotide sequence comprising the sequence set forth in SEQ ID NOS:1 or 3.

20 20. A method for expression of a Bcl-G polypeptide, said method comprising culturing cells of claim 8 under conditions suitable for expression of said Bcl-G.

21. An isolated anti-Bcl-G antibody having specific reactivity with a Bcl-G according to claim 13.

25 22. Antibody according to claim 21, wherein said antibody is a monoclonal antibody.

23. A cell line producing the monoclonal antibody of claim 22.

24. An antibody according to claim 21, wherein said antibody is a polyclonal antibody.

5 25. A composition comprising an amount of the antisense-nucleic acid according to claim 11 effective to inhibit expression of a human Bcl-G and an acceptable carrier capable of delivering Bcl-G to a cell.

26. A transgenic nonhuman mammal expressing exogenous nucleic acid according to claim 2, encoding a Bcl-G.

10 27. A transgenic nonhuman mammal according to claim 26, wherein said nucleic acid encoding said Bcl-G has been mutated, and wherein the Bcl-G so expressed is not native Bcl-G.

15 28. A mutant non-human mammal having a disrupted Bcl-G gene.

29. A transgenic nonhuman mammal according to claim 26, wherein the transgenic nonhuman mammal is a mouse.

20 30. A method for identifying nucleic acids encoding a mammalian Bcl-G, comprising contacting a sample containing nucleic acids with one or more oligonucleotides according to claim 9, wherein said contacting is effected under high stringency hybridization conditions, and identifying a nucleic acid  
25 that hybridizes to said oligonucleotide.

31. A method of detecting a Bcl-G nucleic acid molecule in a sample, comprising contacting said sample with two or more Bcl-G oligonucleotides of claim 9, amplifying a nucleic acid molecule, and detecting said amplification.

32. The method of claim 31, wherein said amplification is performed using polymerase chain reaction.

33. A method for detecting the presence of a human Bcl-G in a sample, comprising contacting a sample with an antibody according to claim 21, and detecting the presence of specific binding of said antibody to said sample, thereby detecting the presence of a human Bcl-G in said sample.

34. Single stranded nucleic acid primers for amplification of a Bcl-G nucleic acid, wherein said primers comprise a nucleic acid sequence derived from the nucleic acid sequences set forth as SEQ ID NOS:1 or 3.

35. A method for modulating the activity of an oncogenic polypeptide, comprising contacting said oncogenic polypeptide with a substantially pure Bcl-G, or an oncogenic protein-binding fragment thereof.

36. A method of identifying an effective agent that alters the association of a Bcl-G with a Bcl-G associated polypeptide (BAP), comprising the steps of:

(a) contacting said Bcl-G and said BAP polypeptide, under conditions that allow said Bcl-G and BAP polypeptide to associate, with a compound; and

(b) detecting the altered association of said Bcl-G and BAP polypeptide, thereby identifying a compound that is an effective agent for altering the association of said Bcl-G with BAP.

5

37. The method of claim 36, wherein said compound is a drug.

38. The method of claim 36, wherein said compound is a polypeptide.

10

39. A method for modulating an activity mediated by a Bcl-G polypeptide, comprising contacting said Bcl-G polypeptide with an effective, modulating amount of an agent identified by claim 36.

15

40. The method of claim 39, wherein said modulated activity is the binding of Bcl-G to a Bcl-2 family member.

41. A method of modulating the level apoptosis in a cell, comprising the steps of:

20

(a) introducing a nucleic acid molecule encoding a Bcl-G into the cell; and

(b) expressing said Bcl-G in said cell, wherein the expression of said Bcl-G modulates apoptosis in said cell.

42. A method of modulating the level of apoptosis in a cell, comprising introducing an antisense nucleotide sequence into the cell, wherein said antisense nucleotide sequence specifically hybridizes to a nucleic acid molecule encoding a Bcl-G, wherein said hybridization reduces or inhibits the expression of said Bcl-G in said cell.

43. A therapeutic composition comprising a pharmaceutically acceptable carrier and a compound selected from the group consisting of a Bcl-G polypeptide, a functional fragment of said Bcl-G, a Bcl-G modulating compound identified according to claim 36, and an anti-Bcl-G antibody.

44. A method of treating a pathology characterized by abnormal cell proliferation, comprising administering an effective amount of the composition according to claim 43.

45. A method of diagnosing a pathology characterized by an increased or decreased level of a Bcl-G in a subject, comprising the steps of:

- (a) obtaining a test sample from the subject;
- (b) contacting said sample with an agent that can bind said Bcl-G under suitable conditions, wherein said conditions allow specific binding of said agent to said Bcl-G; and
- (c) comparing the amount of said specific binding in said test sample with the amount of specific binding in a control sample, wherein an increased or decreased amount of said

specific binding in said test sample as compared to said control sample is diagnostic of a pathology.

5           46. The method of claim 45, wherein said agent is selected from the group consisting of an anti-Bcl-G antibody, a Bcl-G-associated-protein (BAP), and a Bcl-G nucleic acid.

10           47. A method of modulating the level of apoptosis in a cell, comprising contacting the cell with a compound that effectively alters the association of Bcl-G with a Bcl-G-associated-protein in the cell, or that effectively alters the activity of a Bcl-G in the cell.

15           48. A chimeric protein comprising a domain selected from the group consisting of BH3 (SEQ ID NOS:5 or 9) and BH2 (SEQ ID NOS:6 or 18).

          49. A method of modulating interactions between Bcl-G and Bcl-2, comprising contacting a Bcl-G polypeptide with the agent of claim 36.

20           50. A method of diagnosing cancer or monitoring cancer therapy comprising contacting a test sample from a patient with the antibody of claim 21.

25           51. A method of assessing prognosis of patients with cancer comprising contacting a test sample from a patient with the antibody of claim 21.



52. A method of diagnosing cancer or monitoring cancer therapy comprising contacting a test sample from a patient with the oligonucleotide of claim 9.

5 53. A method of assessing prognosis of patients with cancer comprising contacting a test sample from a patient with the oligonucleotide of claim 9.




FIGURE 1

Bcl-G<sub>L</sub>

```

1 - ATGTGTAGCACCAGTGGGTGTGACCTGGAAGAAATCCCCCTAGATGATGATGACCTAAAC - 60
- M C S T S G C D L E E I P L D D D D L N
61 - ACCATAGAATTCAAAATCCTCGCTACTACACCAGACATCATGTCTTCAAGAGCACCCCT - 120
- T I E F K I L A Y Y T R H H V F K S T P
121 - GCTCTCTTCTCAOCAAAGCTGCTGAGAACAAGAAGTTTGTCCAGAGGGGCTGGGGAAT - 180
- A L F S P K L L R T R S L S Q R G L G N
181 - TGTTACAGCAAATGAGTCATGGACAGAGGTGTCATGGCCCTGCAGAAATTCCCAATCCAGT - 240
- C S A N E S W T E V S W P C R N S Q S S
241 - GAGAAGGCCATAAACCTTGGCAAGAAAAGTCTTCTTGGAAAGCATICTTTGGAGTAGTG - 300
- E K A I N L G K K K S S W K A F F G V V
301 - GAGAAGGAAGATTGCGAGAGCAGGCTGCCAAGGTCTCTGCTCAGGGTCAAAGGACGTTG - 360
- E K E D S Q S T P A K V S A Q G Q R T L
361 - GAATACCAAGATTGCGACAGCCAGCAGTGGTCCAGGTGCTTCTTCAAGTGGAGCAGTGC - 420
- E Y Q D S H S Q Q W S R C L S N V E Q C
421 - TTGGAGCATGAAGCTGTGGACCCCAAAGTCATTTCCATTGCCAACCGAGTAGCTGAAATT - 480
- L E H E A V D P K V I S I A N R V A E I
481 - GTTTACTCCTGGCCACCACCACAAGGACCCAGGCAGGAGGCTTCAAGTCCAAGAGATT - 540
- V Y S W P P P Q A T Q A G G F K S K E I
541 - TTTGTAACTGAGGGTCTCTCCTTCCAGCTCCAAGGCCACGTGCTGTAGCTTCAAGTTCT - 600
- F V T E G L S F Q L Q G H V P V A S S S
601 - AAGAAAGATGAAGAAGAACAATACTAGCCAAAATTTGTTGAGCTGCTGAAATATTTCAGGA - 660
- K K D E E E Q I L A K I V E L L K Y S G
661 - GATCAGTTGGAAAGAAGCTGAAGAAAGATAAGGCTTTGATGGCCACTTCCAGGATGGG - 720
- D Q L E R K L K K D K A L M G H F Q D G
721 - CTGTCTACTCTGTFTTCAAGACCATCACAGACCAGGTCCCTAATGGGTGTGGACCCAGG - 780
- L S Y S V F K T I T D Q V L M G V D P R
781 - GGAGAATCAGAGGTCAAAGCTCAGGGCTTTAAGGCTGCCCTTGTAAATAGACGTACGGCC - 840
- G E S E V K A Q G F K A A L V I D V T A
841 - AAGCTCACAGCTATTGACAACCAACCGATGAACAGGGTCCCTGGGCTTTGGCACCAGTAC - 900
- K L T A I D N H P M N R V L G F G T K Y
901 - CTGAAAGAGAACTTCTGOCATGGATCCAGCAGCAOGGTGGATGGGAAAAAATACTTTGGG - 960
- L K E N F S P W I Q Q H G G W E K I L G
961 - ATATCACATGAAGAAGTAGACTGA - 984
- I S H E E V D *
    
```

FIGURE 2

```

          10      20      30      40
  ───────────
aatgacatgacagccattccgtggccagggacaccactgc 40
ccaagctggagaccacgaggattcagggactgaagccagc 80
atgggaattcctggtttgagatcagagtcctgagtacctc 120
gtgggaacttgggcactcatccgcaggaggctagacccc 160
cagagaattccttgagtcctaaggcacaggcccaacatgtg 200
          210      220      230      240
  ───────────
tagcaccagtgggtgtgacctggaagaaatccccctagat 240
gatgatgacctaaacaccatagaattcaaaatcctcgct 280
actacaccagacatcatgtcttcaagagcaccctgctct 320
cttctcaccaaagctgctgagaacaagaagttgtcccag 360
aggggcttgggaattgttcagcaaatgagtcattggacag 400
          410      420      430      440
  ───────────
aggtgtcatggccttgcagaaattcccaatccagtgagaa 440
ggccataaaccttggcaagaaaaagcttcttggaaagca 480
ttctttggagtagtggaagaaggaagattcgagagcacgc 520
ctgccaaggtctctgctcaggggtcaaggacgcttggata 560
ccaagattcgcacagccagcagtggtccaggtgtctttct 600
          610      620      630      640
  ───────────
aacgtggagcagtgcttggagcatgaagctgtggacccca 640
aagtcatttccattgccaaccgagtagctgaaattgttta 680
ctcctggccaccaccacaagcagccaggcaggaggcttc 720
aagtccaaagagatTTTTGtaactgagggctctccttcc 760
agctccaaggccacgtgctgtagcttcaagttctaagaa 800
          810      820      830      840
  ───────────
agatgaagaagaacaatactagccaaaattgttgagctg 840
ctgaaatattcaggagatcagttggaaagaaaggacactg 880
ccttcatccccattcccttggttgacaccagcatccaggg 920
ttttccacaggatggtttgatggcctgcatttga 954
  
```

FIGURE 3

Bcl-Gs

```

1 - ATGTGAGCACCCAGTGGGTGACCTGGAGAAATCCCCCTAGATGATGACCTAAC - 60
  - M C S T S G C D L E E I P L D D D L N
61 - ACCATAGAAATCAAATCCCGCCCTACTACACGACATCATGCTCAAGAGCACCCCT - 120
  - T I E F K I L A Y Y T R H H V F K S T P
121 - GCTCTCTTCCACCAAGCTGTGAGAACAAAGATTGTCCAGAGGGCCCTGGGGAAT - 180
  - A L F S P K L L R T R S L S Q R G L G N
181 - TGTTACAGCAATGATGATGACAGAGGTGCATGGCCTTGAGAAATCCCAATCCAGT - 240
  - C S A N E S W T E V S W P C R N S Q S S
241 - GAGAAGCCATAAACCTTGGCAAGAAAAGCTCTTTGGAAAGCATCTTTGGAGTAGTG - 300
  - E K A I N L G K K S S W K A F F G V V
301 - GAGAAGGAGATTCCGAGACACCGCTGCCAAGGTCCTGCTCAGGTCAAAGGACGTTG - 360
  - E K E D S Q S T P A K V S A Q G R T L
361 - GAATCCAGATTCCGACAGCCAGAGTGGTCCAGGTCCTTTTAACTGGAGCAGTGC - 420
  - E Y Q D S H S Q Q W S R C L S N V E Q C
421 - TTGGAGCATGAAGCTGTGGACCCCAAGTCATTTCCATTGCCAACCCAGTAGCTGAAAT - 480
  - L E H E A V D P K V I S I A N R V A E I
481 - GTTACTCTGGCCACCACCAAGCCAGCCAGGAGGCTTCAAGTCCAAAGAGATT - 540
  - V Y S W P P P Q A T Q A G G F K S K E I
541 - TTTGTAAGTGAAGGTCCTCTCCAGCTCCCAAGGCCACGTCCTGAGCTTCAAGTTCT - 600
  - F V T E G L S F Q L Q G H V P V A S S S
601 - AAGAAAGATGAAGAACAAATACTAGCCAAATTTGTGCTGCTGAATATTCAGGA - 660
  - K K D E E Q I L A K I V E L L K Y S G
661 - GATCAGTTGAAAGAGGACATGCTCCATCCCAATCCCTGTTGACACCCAGCATC - 720
  - D Q L E R K D T A F I P I P L V D T S I
721 - CAGGTTTTCCACAGGATGTTGATGGCCTGCATTTGA - 759
  - Q G F P Q D G L M A C I *

```

FIGURE 4




FIGURE 5




FIGURE 6




FIGURE 7






FIGURE 8




FIGURE 9




FIGURE 10




FIGURE 11

## SEQUENCE LISTING

<110> Reed, John C.  
Godzik, Adam  
The Burnham Institute

<120> BCL-G Polypeptides, Encoding Nucleic Acids and Methods  
of Use

<130> FP-LJ 4352

<140>

<141>

<150> US 09/461,641

<151> 1999-12-14

<160> 44

<170> PatentIn Ver. 2.0

<210> 1

<211> 1179

<212> DNA

<213> Homo sapiens

<220>

<221> CDS

<222> (196)..(1179)

<400> 1

aatgacatga cagccattcc gtggccaggg acaccactgc ccaagctgga gaccacgagg 60

atlcagggac tgaagccagc atgggaattc ctggtttgag atcagagtcc tgagtacctc 120

gtgggaactt gggcactcat ccgcaggagg tctagacccc cagagaattc cttgagtcta 180

aggcacagggc ccaac atg tgt agc acc agt ggg tgt gac ctg gaa gaa atc 231

Met Cys Ser Thr Ser Gly Cys Asp Leu Glu Glu Ile

1 5 10

ccc cta gat gat gat gac cta aac acc ata gaa ttc aaa atc ctc gcc 279

Pro Leu Asp Asp Asp Asp Leu Asn Thr Ile Glu Phe Lys Ile Leu Ala

15 20 25

tac tac acc aga cat cat gtc ttc aag agc acc cct gct ctc ttc tca 327

Tyr Tyr Thr Arg His His Val Phe Lys Ser Thr Pro Ala Leu Phe Ser

30 35 40

cca aag ctg ctg aga aca aga agt ttg tcc cag agg ggc ctg ggg aat 375

Pro Lys Leu Leu Arg Thr Arg Ser Leu Ser Gln Arg Gly Leu Gly Asn

45 50 55 60

tgt tca gca aat gag tca tgg aca gag gtg tca tgg cct tgc aga aat 423

Cys Ser Ala Asn Glu Ser Trp Thr Glu Val Ser Trp Pro Cys Arg Asn

65 70 75

tcc caa tcc agt gag aag gcc ata aac ctt ggc aag aaa aag tct tct	471
Ser Gln Ser Ser Glu Lys Ala Ile Asn Leu Gly Lys Lys Lys Ser Ser	
80 85 90	
tgg aaa gca ttc ttt gga gta gtg gag aag gaa gat tcg cag agc acg	519
Trp Lys Ala Phe Phe Gly Val Val Glu Lys Glu Asp Ser Gln Ser Thr	
95 100 105	
cct gcc aag gtc tct gct cag ggt caa agg acg ttg gaa tac caa gat	567
Pro Ala Lys Val Ser Ala Gln Gly Gln Arg Thr Leu Glu Tyr Gln Asp	
110 115 120	
tcg cac agc cag cag tgg tcc agg tgt ctt tct aac gtg gag cag tgc	615
Ser His Ser Gln Gln Trp Ser Arg Cys Leu Ser Asn Val Glu Gln Cys	
125 130 135 140	
ttg gag cat gaa gct gtg gac ccc aaa gtc att tcc att gcc aac cga	663
Leu Glu His Glu Ala Val Asp Pro Lys Val Ile Ser Ile Ala Asn Arg	
145 150 155	
gta gct gaa att gtt tac tcc tgg cca cca cca caa gcg acc cag gca	711
Val Ala Glu Ile Val Tyr Ser Trp Pro Pro Pro Gln Ala Thr Gln Ala	
160 165 170	
gga ggc ttc aag tcc aaa gag att ttt gta act gag ggt ctc tcc ttc	759
Gly Gly Phe Lys Ser Lys Glu Ile Phe Val Thr Glu Gly Leu Ser Phe	
175 180 185	
cag ctc caa ggc cac gtg cct gta gct tca agt tct aag aaa gat gaa	807
Gln Leu Gln Gly His Val Pro Val Ala Ser Ser Ser Lys Lys Asp Glu	
190 195 200	
gaa gaa caa ata cta gcc aaa att gtt gag ctg ctg aaa tat tca gga	855
Glu Glu Gln Ile Leu Ala Lys Ile Val Glu Leu Leu Lys Tyr Ser Gly	
205 210 215 220	
gat cag ttg gaa aga aag ctg aag aaa gat aag gct ttg atg ggc cac	903
Asp Gln Leu Glu Arg Lys Leu Lys Lys Asp Lys Ala Leu Met Gly His	
225 230 235	
ttc cag gat ggg ctg tcc tac tct gtt ttc aag acc atc aca gac cag	951
Phe Gln Asp Gly Leu Ser Tyr Ser Val Phe Lys Thr Ile Thr Asp Gln	
240 245 250	
gtc cta atg ggt gtg gac ccc agg gga gaa tca gag gtc aaa gct cag	999
Val Leu Met Gly Val Asp Pro Arg Gly Glu Ser Glu Val Lys Ala Gln	
255 260 265	
ggc ttt aag gct gcc ctt gta ata gac gtc acg gcc aag ctc aca gct	1047
Gly Phe Lys Ala Ala Leu Val Ile Asp Val Thr Ala Lys Leu Thr Ala	
270 275 280	
att gac aac cac ccg atg aac agg gtc ctg ggc ttt ggc acc aag tac	1095
Ile Asp Asn His Pro Met Asn Arg Val Leu Gly Phe Gly Thr Lys Tyr	
285 290 295 300	
ctg aaa gag aac ttc tcg cca tgg atc cag cag cac ggt gga tgg gaa	1143

Leu Lys Glu Asn Phe Ser Pro Trp Ile Gln Gln His Gly Gly Trp Glu  
 305 310 315

aaa ata ctt ggg ata tca cat gaa gaa gta gac tga 1179  
 Lys Ile Leu Gly Ile Ser His Glu Glu Val Asp  
 320 325

<210> 2  
 <211> 327  
 <212> PRT  
 <213> Homo sapiens

<400> 2  
 Met Cys Ser Thr Ser Gly Cys Asp Leu Glu Glu Ile Pro Leu Asp Asp  
 1 5 10 15

Asp Asp Leu Asn Thr Ile Glu Phe Lys Ile Leu Ala Tyr Tyr Thr Arg  
 20 25 30

His His Val Phe Lys Ser Thr Pro Ala Leu Phe Ser Pro Lys Leu Leu  
 35 40 45

Arg Thr Arg Ser Leu Ser Gln Arg Gly Leu Gly Asn Cys Ser Ala Asn  
 50 55 60

Glu Ser Trp Thr Glu Val Ser Trp Pro Cys Arg Asn Ser Gln Ser Ser  
 65 70 75 80

Glu Lys Ala Ile Asn Leu Gly Lys Lys Lys Ser Ser Trp Lys Ala Phe  
 85 90 95

Phe Gly Val Val Glu Lys Glu Asp Ser Gln Ser Thr Pro Ala Lys Val  
 100 105 110

Ser Ala Gln Gly Gln Arg Thr Leu Glu Tyr Gln Asp Ser His Ser Gln  
 115 120 125

Gln Trp Ser Arg Cys Leu Ser Asn Val Glu Gln Cys Leu Glu His Glu  
 130 135 140

Ala Val Asp Pro Lys Val Ile Ser Ile Ala Asn Arg Val Ala Glu Ile  
 145 150 155 160

Val Tyr Ser Trp Pro Pro Pro Gln Ala Thr Gln Ala Gly Gly Phe Lys  
 165 170 175

Ser Lys Glu Ile Phe Val Thr Glu Gly Leu Ser Phe Gln Leu Gln Gly  
 180 185 190

His Val Pro Val Ala Ser Ser Ser Lys Lys Asp Glu Glu Glu Gln Ile  
 195 200 205

Leu Ala Lys Ile Val Glu Leu Leu Lys Tyr Ser Gly Asp Gln Leu Glu  
 210 215 220

Arg Lys Leu Lys Lys Asp Lys Ala Leu Met Gly His Phe Gln Asp Gly

225					230						235					240
Leu	Ser	Tyr	Ser	Val	Phe	Lys	Thr	Ile	Thr	Asp	Gln	Val	Leu	Met	Gly	
				245					250					255		
Val	Asp	Pro	Arg	Gly	Glu	Ser	Glu	Val	Lys	Ala	Gln	Gly	Phe	Lys	Ala	
			260					265					270			
Ala	Leu	Val	Ile	Asp	Val	Thr	Ala	Lys	Leu	Thr	Ala	Ile	Asp	Asn	His	
		275					280					285				
Pro	Met	Asn	Arg	Val	Leu	Gly	Phe	Gly	Thr	Lys	Tyr	Leu	Lys	Glu	Asn	
	290					295					300					
Phe	Ser	Pro	Trp	Ile	Gln	Gln	His	Gly	Gly	Trp	Glu	Lys	Ile	Leu	Gly	
305					310					315					320	
Ile	Ser	His	Glu	Glu	Val	Asp										
				325												

<210> 3  
 <211> 954  
 <212> DNA  
 <213> Homo sapiens

<220>  
 <221> CDS  
 <222> (196)..(954)

<400> 3  
 aatgacatga cagccattcc gtggccaggg acaccactgc ccaagctgga gaccacgagg 60  
 attcagggac tgaagccagc atgggaattc ctggtttgag atcagagtcc tgagtacctc 120  
 gtgggaactt gggcactcat ccgcaggagg tctagacccc cagagaattc cttgagtcta 180  
 aggcacaggc ccaac atg tgt agc acc agt ggg tgt gac ctg gaa gaa atc 231  
                     Met Cys Ser Thr Ser Gly Cys Asp Leu Glu Glu Ile  
                           1                  5                          10  
 ccc cta gat gat gat gac cta aac acc ata gaa ttc aaa atc ctc gcc 279  
 Pro Leu Asp Asp Asp Asp Leu Asn Thr Ile Glu Phe Lys Ile Leu Ala  
                   15                          20                          25  
 tac tac acc aga cat cat gtc ttc aag agc acc cct gct ctc ttc tca 327  
 Tyr Tyr Thr Arg His His Val Phe Lys Ser Thr Pro Ala Leu Phe Ser  
           30                          35                          40  
 cca aag ctg ctg aga aca aga agt ttg tcc cag agg ggc ctg ggg aat 375  
 Pro Lys Leu Leu Arg Thr Arg Ser Leu Ser Gln Arg Gly Leu Gly Asn  
   45                          50                          55                          60  
 tgt tca gca aat gag tca tgg aca gag gtg tca tgg cct tgc aga aat 423  
 Cys Ser Ala Asn Glu Ser Trp Thr Glu Val Ser Trp Pro Cys Arg Asn  
                   65                          70                          75



tcc caa tcc agt gag aag gcc ata aac ctt ggc aag aaa aag tct tct 471  
 Ser Gln Ser Ser Glu Lys Ala Ile Asn Leu Gly Lys Lys Lys Ser Ser  
 80 85 90

tgg aaa gca ttc ttt gga gta gtg gag aag gaa gat tcg cag agc acg 519  
 Trp Lys Ala Phe Phe Gly Val Val Glu Lys Glu Asp Ser Gln Ser Thr  
 95 100 105

cct gcc aag gtc tct gct cag ggt caa agg acg ttg gaa tac caa gat 567  
 Pro Ala Lys Val Ser Ala Gln Gly Gln Arg Thr Leu Glu Tyr Gln Asp  
 110 115 120

tcg cac agc cag cag tgg tcc agg tgt ctt tct aac gtg gag cag tgc 615  
 Ser His Ser Gln Gln Trp Ser Arg Cys Leu Ser Asn Val Glu Gln Cys  
 125 130 135 140

ttg gag cat gaa gct gtg gac ccc aaa gtc att tcc att gcc aac cga 663  
 Leu Glu His Glu Ala Val Asp Pro Lys Val Ile Ser Ile Ala Asn Arg  
 145 150 155

gta gct gaa att gtt tac tcc tgg cca cca cca caa gcg acc cag gca 711  
 Val Ala Glu Ile Val Tyr Ser Trp Pro Pro Pro Gln Ala Thr Gln Ala  
 160 165 170

gga ggc ttc aag tcc aaa gag att ttt gta act gag ggt ctc tcc ttc 759  
 Gly Gly Phe Lys Ser Lys Glu Ile Phe Val Thr Glu Gly Leu Ser Phe  
 175 180 185

cag ctc caa ggc cac gtg cct gta gct tca agt tct aag aaa gat gaa 807  
 Gln Leu Gln Gly His Val Pro Val Ala Ser Ser Ser Lys Lys Asp Glu  
 190 195 200

gaa gaa caa ata cta gcc aaa att gtt gag ctg ctg aaa tat tca gga 855  
 Glu Glu Gln Ile Leu Ala Lys Ile Val Glu Leu Leu Lys Tyr Ser Gly  
 205 210 215 220

gat cag ttg gaa aga aag gac act gcc ttc atc ccc att ccc ttg gtt 903  
 Asp Gln Leu Glu Arg Lys Asp Thr Ala Phe Ile Pro Ile Pro Leu Val  
 225 230 235

gac acc agc atc cag ggt ttt cca cag gat ggt ttg atg gcc tgc att 951  
 Asp Thr Ser Ile Gln Gly Phe Pro Gln Asp Gly Leu Met Ala Cys Ile  
 240 245 250

tga 954

<210> 4  
 <211> 252  
 <212> PRT  
 <213> Homo sapiens

<400> 4  
 Met Cys Ser Thr Ser Gly Cys Asp Leu Glu Glu Ile Pro Leu Asp Asp  
 1 5 10 15

Asp Asp Leu Asn Thr Ile Glu Phe Lys Ile Leu Ala Tyr Tyr Thr Arg  
 20 25 30

His His Val Phe Lys Ser Thr Pro Ala Leu Phe Ser Pro Lys Leu Leu  
 35 40 45

Arg Thr Arg Ser Leu Ser Gln Arg Gly Leu Gly Asn Cys Ser Ala Asn  
 50 55 60

Glu Ser Trp Thr Glu Val Ser Trp Pro Cys Arg Asn Ser Gln Ser Ser  
 65 70 75 80

Glu Lys Ala Ile Asn Leu Gly Lys Lys Lys Ser Ser Trp Lys Ala Phe  
 85 90 95

Phe Gly Val Val Glu Lys Glu Asp Ser Gln Ser Thr Pro Ala Lys Val  
 100 105 110

Ser Ala Gln Gly Gln Arg Thr Leu Glu Tyr Gln Asp Ser His Ser Gln  
 115 120 125

Gln Trp Ser Arg Cys Leu Ser Asn Val Glu Gln Cys Leu Glu His Glu  
 130 135 140

Ala Val Asp Pro Lys Val Ile Ser Ile Ala Asn Arg Val Ala Glu Ile  
 145 150 155 160

Val Tyr Ser Trp Pro Pro Pro Gln Ala Thr Gln Ala Gly Gly Phe Lys  
 165 170 175

Ser Lys Glu Ile Phe Val Thr Glu Gly Leu Ser Phe Gln Leu Gln Gly  
 180 185 190

His Val Pro Val Ala Ser Ser Ser Lys Lys Asp Glu Glu Glu Gln Ile  
 195 200 205

Leu Ala Lys Ile Val Glu Leu Leu Lys Tyr Ser Gly Asp Gln Leu Glu  
 210 215 220

Arg Lys Asp Thr Ala Phe Ile Pro Ile Pro Leu Val Asp Thr Ser Ile  
 225 230 235 240

Gln Gly. Phe Pro Gln Asp Gly Leu Met Ala Cys Ile  
 245 250

<210> 5  
 <211> 9  
 <212> PRT  
 <213> Homo sapiens

<400> 5  
 Leu Lys Tyr Ser Gly Asp Gln Leu Glu  
 1 5

<210> 6

<211> 10  
 <212> PRT  
 <213> Homo sapiens

<400> 6  
 Pro Trp Ile Gln Gln His Gly Gly Trp Glu  
 1 5 10

<210> 7  
 <211> 22  
 <212> DNA  
 <213> Artificial Sequence

<220>  
 <223> Description of Artificial Sequence: primer

<400> 7  
 gtacttggtg ccaaagccca gg 22

<210> 8  
 <211> 28  
 <212> DNA  
 <213> Artificial Sequence

<220>  
 <223> Description of Artificial Sequence: primer

<400> 8  
 gacatgatgt ctggtgtagt aggcgagg 28

<210> 9  
 <211> 15  
 <212> PRT  
 <213> Homo sapiens

<400> 9  
 Ile Val Glu Leu Leu Lys Tyr Ser Gly Asp Gln Leu Glu Arg Lys  
 1 5 10 15

<210> 10  
 <211> 15  
 <212> PRT  
 <213> Homo sapiens

<400> 10  
 Leu Ser Glu Cys Leu Lys Arg Ile Gly Asp Glu Leu Asp Ser Asn  
 1 5 10 15

<210> 11  
 <211> 15  
 <212> PRT  
 <213> Homo sapiens

&lt;400&gt; 11

Val Gly Arg Gln Leu Ala Ile Ile Gly Asp Asp Ile Asn Arg Arg  
 1 5 10 15

&lt;210&gt; 12

&lt;211&gt; 15

&lt;212&gt; PRT

&lt;213&gt; Homo sapiens

&lt;400&gt; 12

Ile Ala Arg His Leu Ala Gln Val Gly Asp Ser Met Asp Arg Ser  
 1 5 10 15

&lt;210&gt; 13

&lt;211&gt; 15

&lt;212&gt; PRT

&lt;213&gt; Homo sapiens

&lt;400&gt; 13

Leu Ala Leu Arg Leu Ala Cys Ile Gly Asp Glu Met Asp Val Ser  
 1 5 10 15

&lt;210&gt; 14

&lt;211&gt; 15

&lt;212&gt; PRT

&lt;213&gt; Homo sapiens

&lt;400&gt; 14

Ala Leu Glu Thr Leu Arg Arg Val Gly Asp Gly Val Gln Arg Asn  
 1 5 10 15

&lt;210&gt; 15

&lt;211&gt; 15

&lt;212&gt; PRT

&lt;213&gt; Homo sapiens

&lt;400&gt; 15

Val Lys Gln Ala Leu Arg Glu Ala Gly Asp Glu Phe Glu Leu Arg  
 1 5 10 15

&lt;210&gt; 16

&lt;211&gt; 15

&lt;212&gt; PRT

&lt;213&gt; Homo sapiens

&lt;400&gt; 16

Leu His Gln Ala Met Arg Ala Ala Gly Asp Glu Phe Glu Thr Arg  
 1 5 10 15

&lt;210&gt; 17

<211> 15  
 <212> PRT  
 <213> Homo sapiens

<400> 17  
 Val His Leu Thr Leu Arg Gln Ala Gly Asp Asp Phe Ser Arg Arg  
 1 5 10 15

<210> 18  
 <211> 8  
 <212> PRT  
 <213> Homo sapiens

<400> 18  
 Trp Ile Gln Gln His Gly Gly Trp  
 1 5

<210> 19  
 <211> 8  
 <212> PRT  
 <213> Homo sapiens

<400> 19  
 Trp Ile Gln Asp Gln Gly Gly Trp  
 1 5

<210> 20  
 <211> 8  
 <212> PRT  
 <213> Homo sapiens

<400> 20  
 Trp Ile Ala Gln Arg Gly Gly Trp  
 1 5

<210> 21  
 <211> 8  
 <212> PRT  
 <213> Homo sapiens

<400> 21  
 Trp Leu Arg Arg Arg Gly Gly Trp  
 1 5

<210> 22  
 <211> 8  
 <212> PRT  
 <213> Homo sapiens

<400> 22  
 Trp Ile Arg Gln Asn Gly Gly Trp  
 1 5

<210> 23  
 <211> 8  
 <212> PRT  
 <213> Homo sapiens

<400> 23  
 Trp Leu Val Lys Gln Arg Gly Trp  
 1 5

<210> 24  
 <211> 8  
 <212> PRT  
 <213> Homo sapiens

<400> 24  
 Trp Ile Gln Glu Asn Gly Gly Trp  
 1 5

<210> 25  
 <211> 8  
 <212> PRT  
 <213> Homo sapiens

<400> 25  
 Trp Ile His Ser Ser Gly Gly Trp  
 1 5

<210> 26  
 <211> 8  
 <212> PRT  
 <213> Homo sapiens

<400> 26  
 Trp Ile Gln Asp Asn Gly Gly Trp  
 1 5

<210> 27  
 <211> 35  
 <212> DNA  
 <213> Artificial Sequence

<220>  
 <223> Description of Artificial Sequence: synthetic primer

<400> 27  
 ggctcgagcg atgtgtagca ccagtgggtg tgacc

35

<210> 28  
 <211> 35

<212> DNA  
<213> Artificial Sequence

<220>  
<223> Description of Artificial Sequence: synthetic primer

<400> 28  
ccaagcttta agtctacttc ttcattgat atccc 35

<210> 29  
<211> 29  
<212> DNA  
<213> Artificial Sequence

<220>  
<223> Description of Artificial Sequence: synthetic primer

<400> 29  
ccaagcttta aaatgcaggc catcaaacc 29

<210> 30  
<211> 35  
<212> DNA  
<213> Artificial Sequence

<220>  
<223> Description of Artificial Sequence: synthetic primer

<400> 30  
ggctcgagcg atgtgtagca ccagtgggtg tgacc 35

<210> 31  
<211> 35  
<212> DNA  
<213> Artificial Sequence

<220>  
<223> Description of Artificial Sequence: synthetic primer

<400> 31  
ccgatccgg ctagtatttg ttcttcttca tcttt 35

<210> 32  
<211> 32  
<212> DNA  
<213> Artificial Sequence

<220>  
<223> Description of Artificial Sequence: synthetic

primer

<400> 32  
ccggatccga cactgccttc atccccattc cc 32

<210> 33  
<211> 29  
<212> DNA  
<213> Artificial Sequence

<220>  
<223> Description of Artificial Sequence: synthetic  
primer

<400> 33  
ccaagcttta aatgcaggc catcaaacc 29

<210> 34  
<211> 43  
<212> DNA  
<213> Artificial Sequence

<220>  
<223> Description of Artificial Sequence: synthetic  
primer

<400> 34  
gccaaaattg ttgagctgga gaaatattca ggagatcagt tgg 43

<210> 35  
<211> 43  
<212> DNA  
<213> Artificial Sequence

<220>  
<223> Description of Artificial Sequence: synthetic  
primer

<400> 35  
ccaactgatc tctgaaat tctccagct caacaatttt ggc 43

<210> 36  
<211> 28  
<212> DNA  
<213> Artificial Sequence

<220>  
<223> Description of Artificial Sequence: synthetic  
primer

<400> 36  
ctgagggtct ctcttccag ctccaagg 28



<210> 37  
<211> 28  
<212> DNA  
<213> Artificial Sequence

<220>  
<223> Description of Artificial Sequence: synthetic primer

<400> 37  
ggccgtgacg tctattacaa ggcagcc 28

<210> 38  
<211> 27  
<212> DNA  
<213> Artificial Sequence

<220>  
<223> Description of Artificial Sequence: synthetic primer

<400> 38  
caaggaatg gggatgaagg cagtgtc 27

<210> 39  
<211> 26  
<212> DNA  
<213> Artificial Sequence

<220>  
<223> Description of Artificial Sequence: synthetic primer

<400> 39  
tgaaggtcgg agtcaacgga tttggt 26

<210> 40  
<211> 24  
<212> DNA  
<213> Artificial Sequence

<220>  
<223> Description of Artificial Sequence: synthetic primer

<400> 40  
catgtgggcc atgaggtcca ccac 24

<210> 41  
<211> 987  
<212> DNA  
<213> Mus musculus

<220>  
 <221> CDS  
 <222> (1)..(987)

<220>  
 <221> unsure  
 <222> (319)  
 <223> unknown nucleotide

<400> 41  
 atg tgc agc acc agt gtg tat gac ctg gaa gac att ccc ctg gag gat 48  
 Met Cys Ser Thr Ser Val Tyr Asp Leu Glu Asp Ile Pro Leu Glu Asp  
 1 5 10 15

gat gat cca aac agc ata gag ttc aaa atc ctg gcc ttc tac gcc aga 96  
 Asp Asp Pro Asn Ser Ile Glu Phe Lys Ile Leu Ala Phe Tyr Ala Arg  
 20 25 30

cac cat gtc ttc aag aac acc ccg gct gtc ttc tcg ccc aag ctc tcc 144  
 His His Val Phe Lys Asn Thr Pro Ala Val Phe Ser Pro Lys Leu Ser  
 35 40 45

aga aca agg agt ctg tcc cag aaa gcc ctg ggg act tgg tca act gat 192  
 Arg Thr Arg Ser Leu Ser Gln Lys Ala Leu Gly Thr Trp Ser Thr Asp  
 50 55 60

tcc tgg aca cag gta tca ttg cct tgc aga ggt tcc ccc tcc agc gaa 240  
 Ser Trp Thr Gln Val Ser Leu Pro Cys Arg Gly Ser Pro Ser Ser Glu  
 65 70 75 80

aag aac atc agc ttg ggc aag aag aag tct tct tgg aga aca ctc ttc 288  
 Lys Asn Ile Ser Leu Gly Lys Lys Lys Ser Ser Trp Arg Thr Leu Phe  
 85 90 95

agg gtg gcc gag aag gag gaa ggc ctg ccg ngc tcc cca aag gag atc 336  
 Arg Val Ala Glu Lys Glu Glu Gly Leu Pro Xaa Ser Pro Lys Glu Ile  
 100 105 110

cga gct cag ggt cct cag ggc ccc ttc ccg gta gag cgg cag agt ggc 384  
 Arg Ala Gln Gly Pro Gln Gly Pro Phe Pro Val Glu Arg Gln Ser Gly  
 115 120 125

ttc cac aac cag cac tgg ccc agg tct ctg agc agt gtg gag cag ccc 432  
 Phe His Asn Gln His Trp Pro Arg Ser Leu Ser Ser Val Glu Gln Pro  
 130 135 140

tgg aga gtg aag ttg tgg att cca aag tgg ctt gta ttg cca aca gag 480  
 Trp Arg Val Lys Leu Trp Ile Pro Lys Trp Leu Val Leu Pro Thr Glu  
 145 150 155 160

tgg ctg aaa ttg ttt act cct ggc cac cac cag atg tca tcc aca gcc 528  
 Trp Leu Lys Leu Phe Thr Pro Gly His His Gln Met Ser Ser Thr Ala  
 165 170 175

agg gag gaa gcc agc tca aag aga ggg tct cgg aga ttt ttg tac ttc 576  
 Arg Glu Glu Ala Ser Ser Lys Arg Gly Ser Arg Arg Phe Leu Tyr Phe

agg ttt gaa gga cct tgg gac tct aag aat aaa gat ggt gaa gac caa	624
Arg Phe Glu Gly Pro Trp Asp Ser Lys Asn Lys Asp Gly Glu Asp Gln	
195 200 205	
ata ata agc aag att gtt gag ctg ctg aaa tcc tcg ggg gat cag ttg	672
Ile Ile Ser Lys Ile Val Glu Leu Leu Lys Ser Ser Gly Asp Gln Leu	
210 215 220	
gga aga gag ata aag aaa gac aag gct ttg atg agc agc ttc cag gac	720
Gly Arg Glu Ile Lys Lys Asp Lys Ala Leu Met Ser Ser Phe Gln Asp	
225 230 235 240	
ggg ctg tcc tac tca acg ttc aag acc atc aca gac ctg ttc ctg agg	768
Gly Leu Ser Tyr Ser Thr Phe Lys Thr Ile Thr Asp Leu Phe Leu Arg	
245 250 255	
gac gtg gac acc aga gga gaa tca gag gtc aaa gct cgg ggc ttc aag	816
Asp Val Asp Thr Arg Gly Glu Ser Glu Val Lys Ala Arg Gly Phe Lys	
260 265 270	
gct gcc ctt gca ata gac gcc atc gcc aag ctc acg gca tcg gac aac	864
Ala Ala Leu Ala Ile Asp Ala Ile Ala Lys Leu Thr Ala Ser Asp Asn	
275 280 285	
cac cca atg aat aga atg ctg ggc ttc ggg acc aag tac cta aaa gag	912
His Pro Met Asn Arg Met Leu Gly Phe Gly Thr Lys Tyr Leu Lys Glu	
290 295 300	
tac ttc tcc ccc tgg gtt cag cag aat ggc gga tgg gaa aaa ata ctt	960
Tyr Phe Ser Pro Trp Val Gln Gln Asn Gly Gly Trp Glu Lys Ile Leu	
305 310 315 320	
ggg atc tca cat gaa gaa gta gac tga	987
Gly Ile Ser His Glu Glu Val Asp	
325	

<210> 42  
 <211> 328  
 <212> PRT  
 <213> Mus musculus

<220>  
 <221> 107  
 <222> unsure  
 <223> Xaa = unknown amino acid

<400> 42  
 Met Cys Ser Thr Ser Val Tyr Asp Leu Glu Asp Ile Pro Leu Glu Asp  
 1 5 10 15  
 Asp Asp Pro Asn Ser Ile Glu Phe Lys Ile Leu Ala Phe Tyr Ala Arg  
 20 25 30  
 His His Val Phe Lys Asn Thr Pro Ala Val Phe Ser Pro Lys Leu Ser

	35				40					45					
Arg	Thr	Arg	Ser	Leu	Ser	Gln	Lys	Ala	Leu	Gly	Thr	Trp	Ser	Thr	Asp
	50					55					60				
Ser	Trp	Thr	Gln	Val	Ser	Leu	Pro	Cys	Arg	Gly	Ser	Pro	Ser	Ser	Glu
65					70					75					80
Lys	Asn	Ile	Ser	Leu	Gly	Lys	Lys	Lys	Ser	Ser	Trp	Arg	Thr	Leu	Phe
				85					90					95	
Arg	Val	Ala	Glu	Lys	Glu	Glu	Gly	Leu	Pro	Xaa	Ser	Pro	Lys	Glu	Ile
			100					105					110		
Arg	Ala	Gln	Gly	Pro	Gln	Gly	Pro	Phe	Pro	Val	Glu	Arg	Gln	Ser	Gly
		115					120					125			
Phe	His	Asn	Gln	His	Trp	Pro	Arg	Ser	Leu	Ser	Ser	Val	Glu	Gln	Pro
	130					135					140				
Trp	Arg	Val	Lys	Leu	Trp	Ile	Pro	Lys	Trp	Leu	Val	Leu	Pro	Thr	Glu
145					150					155					160
Trp	Leu	Lys	Leu	Phe	Thr	Pro	Gly	His	His	Gln	Met	Ser	Ser	Thr	Ala
				165					170					175	
Arg	Glu	Glu	Ala	Ser	Ser	Lys	Arg	Gly	Ser	Arg	Arg	Phe	Leu	Tyr	Phe
			180					185					190		
Arg	Phe	Glu	Gly	Pro	Trp	Asp	Ser	Lys	Asn	Lys	Asp	Gly	Glu	Asp	Gln
		195					200					205			
Ile	Ile	Ser	Lys	Ile	Val	Glu	Leu	Leu	Lys	Ser	Ser	Gly	Asp	Gln	Leu
	210					215					220				
Gly	Arg	Glu	Ile	Lys	Lys	Asp	Lys	Ala	Leu	Met	Ser	Ser	Phe	Gln	Asp
225					230					235					240
Gly	Leu	Ser	Tyr	Ser	Thr	Phe	Lys	Thr	Ile	Thr	Asp	Leu	Phe	Leu	Arg
				245					250					255	
Asp	Val	Asp	Thr	Arg	Gly	Glu	Ser	Glu	Val	Lys	Ala	Arg	Gly	Phe	Lys
			260					265					270		
Ala	Ala	Leu	Ala	Ile	Asp	Ala	Ile	Ala	Lys	Leu	Thr	Ala	Ser	Asp	Asn
		275					280						285		
His	Pro	Met	Asn	Arg	Met	Leu	Gly	Phe	Gly	Thr	Lys	Tyr	Leu	Lys	Glu
	290					295					300				
Tyr	Phe	Ser	Pro	Trp	Val	Gln	Gln	Asn	Gly	Gly	Trp	Glu	Lys	Ile	Leu
305					310					315					320
Gly	Ile	Ser	His	Glu	Glu	Val	Asp								
				325											

<210> 43

<211> 31

<212> DNA

<213> Artificial Sequence

<220>

<223> Description of Artificial Sequence: synthetic primer

<400> 43

gggctcgaga tgtgcagcac cagtgtgtat g

31

<210> 44

<211> 35

<212> DNA

<213> Artificial Sequence

<220>

<223> Description of Artificial Sequence: synthetic primer

<400> 44

ccaagcttta agtctacttc ttcattgtgat atccc

35

(19) World Intellectual Property Organization  
International Bureau



(43) International Publication Date  
21 June 2001 (21.06.2001)

PCT

(10) International Publication Number  
WO 01/44282 A3

- (51) International Patent Classification<sup>7</sup>: C12N 15/12, 15/11, 15/62, C07K 14/47, 16/18, A01K 67/027, A61K 38/17, 48/00, C12Q 1/68, G01N 33/68, 33/53
- (74) Agents: CADENA, Deborah, L. et al.; Campbell & Flores LLP, 7th floor, 4370 La Jolla Village Drive, San Diego, CA 92122 (US).
- (21) International Application Number: PCT/US00/33793
- (22) International Filing Date: 13 December 2000 (13.12.2000)
- (25) Filing Language: English
- (26) Publication Language: English
- (30) Priority Data: 09/461.641 14 December 1999 (14.12.1999) US
- (63) Related by continuation (CON) or continuation-in-part (CIP) to earlier application: US 09/461.641 (CIP) Filed on 14 December 1999 (14.12.1999)
- (71) Applicant (for all designated States except US): THE BURNHAM INSTITUTE [US/US]; 10901 N. Torrey Pines Road, La Jolla, CA 92037 (US).
- (72) Inventors; and
- (75) Inventors/Applicants (for US only): REED, John, C. [US/US]; 17044 El Camino Real, P.O. Box 137, Rancho Santa Fe, CA 92067 (US). GODZIK, Adam [PL/US]; 9184 Buckwheat Street, San Diego, CA 92129 (US).
- (81) Designated States (national): AE, AG, AL, AM, AT, AU, AZ, BA, BB, BG, BR, BY, BZ, CA, CH, CN, CR, CU, CZ, CZ (utility model), DE, DE (utility model), DK, DK (utility model), DM, DZ, EE, EE (utility model), ES, FI, FI (utility model), GB, GD, GE, GH, GM, HR, HU, ID, IL, IN, IS, JP, KE, KG, KP, KR, KZ, LC, LK, LR, LS, LT, LU, LV, MA, MD, MG, MK, MN, MW, MX, MZ, NO, NZ, PL, PT, RO, RU, SD, SE, SG, SI, SK, SK (utility model), SL, TJ, TM, TR, TT, TZ, UA, UG, US, UZ, VN, YU, ZA, ZW.
- (84) Designated States (regional): ARIPO patent (GH, GM, KE, LS, MW, MZ, SD, SL, SZ, TZ, UG, ZW), Eurasian patent (AM, AZ, BY, KG, KZ, MD, RU, TJ, TM), European patent (AT, BE, CH, CY, DE, DK, ES, FI, FR, GB, GR, IE, IT, LU, MC, NL, PT, SE, TR), OAPI patent (BF, BJ, CF, CG, CI, CM, GA, GN, GW, ML, MR, NE, SN, TD, TG).
- Published:  
— with international search report
- (88) Date of publication of the international search report: 21 February 2002
- For two-letter codes and other abbreviations, refer to the "Guidance Notes on Codes and Abbreviations" appearing at the beginning of each regular issue of the PCT Gazette.



WO 01/44282 A3

(54) Title: BCL-G POLYPEPTIDES, ENCODING NUCLEIC ACIDS AND METHODS OF USE

(57) Abstract: The invention provides Bcl-G polypeptides and encoding nucleic acids. Bcl-G polypeptides include Bcl-G<sub>1</sub> and Bcl-G<sub>5</sub>. The invention also provides mouse Bcl-G. The invention also provides vectors containing Bcl-G nucleic acids, host cells containing such vectors, Bcl-G anti-sense nucleic acids and related compositions. The invention additionally provides Bcl-G oligonucleotides that can be used to hybridize to or amplify a Bcl-G nucleic acid. Anti-Bcl-G specific antibodies are also provided. Further provided are kits containing Bcl-G nucleic acids or Bcl-G specific antibodies. Such kits and reagents can be used to diagnose cancer, monitor response to therapy, or predict the prognosis of a cancer patient. The invention additionally provides methods of modulating apoptosis using Bcl-G polypeptides, encoding nucleic acids, or compounds that modulate the activity or expression of Bcl-G polypeptides. The methods for modulating apoptosis can be used to treat diseases such as cancer.

# INTERNATIONAL SEARCH REPORT

International Application No  
PCT/US 00/33793

**A. CLASSIFICATION OF SUBJECT MATTER**

IPC 7 C12N15/12 C12N15/11 C12N15/62 C07K14/47 C07K16/18  
A01K67/027 A61K38/17 A61K48/00 C12Q1/68 G01N33/68  
G01N33/53

According to International Patent Classification (IPC) or to both national classification and IPC

**B. FIELDS SEARCHED**

Minimum documentation searched (classification system followed by classification symbols)  
IPC 7 C07K C12N

Documentation searched other than minimum documentation to the extent that such documents are included in the fields searched

Electronic data base consulted during the international search (name of data base and, where practical, search terms used)

CHEM ABS Data, EMBASE, EPO-Internal, EMBL, PASCAL, MEDLINE, SCISEARCH

**C. DOCUMENTS CONSIDERED TO BE RELEVANT**

Category °	Citation of document, with indication, where appropriate, of the relevant passages	Relevant to claim No.
X	DATABASE EMBL 'Online! 31 July 1997 (1997-07-31) MARRA M. ET AL.: " Knowles Solter mouse 2 cell Mus musculus cDNA clone " retrieved from EBI Database accession no. AA536718 XP002174348	1-6
Y	--- -/--	7-34, 43, 45, 46, 48, 50-53

Further documents are listed in the continuation of box C.

Patent family members are listed in annex.

° Special categories of cited documents :

- \*A\* document defining the general state of the art which is not considered to be of particular relevance
- \*E\* earlier document but published on or after the international filing date
- \*L\* document which may throw doubts on priority claim(s) or which is cited to establish the publication date of another citation or other special reason (as specified)
- \*O\* document referring to an oral disclosure, use, exhibition or other means
- \*P\* document published prior to the international filing date but later than the priority date claimed

- \*T\* later document published after the international filing date or priority date and not in conflict with the application but cited to understand the principle or theory underlying the invention
- \*X\* document of particular relevance; the claimed invention cannot be considered novel or cannot be considered to involve an inventive step when the document is taken alone
- \*Y\* document of particular relevance; the claimed invention cannot be considered to involve an inventive step when the document is combined with one or more other such documents, such combination being obvious to a person skilled in the art.
- \*&\* document member of the same patent family

Date of the actual completion of the international search

10 August 2001

Date of mailing of the international search report

24/08/2001

Name and mailing address of the ISA

European Patent Office, P.B. 5818 Patentlaan 2  
 NL - 2280 HV Rijswijk  
 Tel. (+31-70) 340-2040, Tx. 31 651 epo nl,  
 Fax: (+31-70) 340-3016

Authorized officer

Gurdjian, D

## INTERNATIONAL SEARCH REPORT

Int :ional Application No

PCT/US 00/33793

## C.(Continuation) DOCUMENTS CONSIDERED TO BE RELEVANT

Category °	Citation of document, with indication, where appropriate, of the relevant passages	Relevant to claim No.
X	DATABASE EMBL 'Online! 26 April 1999 (1999-04-26) MARRA M. ET AL. : "Stratagene mouse testis (#937308) Mus musculus cDNA clone" retrieved from EBI Database accession no. AI614194 XP002174349	1-6
Y	abstract	7-34, 43, 45, 46, 48, 50-53
Y	--- WO 95 28497 A (JOLLA CANCER RES FOUND) 26 October 1995 (1995-10-26)  claims 1-14; figures 5, SEQ.ID.24 ---	7-34, 43, 45, 46, 48, 50-53
Y	--- WO 95 00642 A (ARCH DEV CORP ;NUNEZ GABRIEL (US); BOISE LAWRENCE H (US); REGENT O) 5 January 1995 (1995-01-05) abstract; claims 1-45; figures 1-4 ---	7-34, 43, 45, 46, 48, 50-53
A	--- WO 97 45128 A (APOPTOSIS TECHNOLOGY INC) 4 December 1997 (1997-12-04) abstract; claim 2; figures 2,8 ---	48
A	--- US 5 691 179 A (KORSMEYER STANLEY J) 25 November 1997 (1997-11-25) column 2, paragraph 3 column 28, paragraph 3 - paragraph 4 ---	48
T	--- GUO, BIN ET AL: "Bcl - G, a novel pro-apoptotic member of the Bcl-2 family" J. BIOL. CHEM. (2001), 276(4), 2780-2785 , XP002174347 the whole document -----	1-34, 43, 45, 46, 48, 50-53



**FURTHER INFORMATION CONTINUED FROM PCT/ISA/ 210**

Continuation of Box I.2

Claims Nos.: 35,43,44 partly and 36-40,47,49

Claims 35,43,44,46 partly and 36-40,47,49 relating to modulators to the BCL-g polypeptide could not be searched as its subject-matter was insufficiently disclosed

The applicant's attention is drawn to the fact that claims, or parts of claims, relating to inventions in respect of which no international search report has been established need not be the subject of an international preliminary examination (Rule 66.1(e) PCT). The applicant is advised that the EPO policy when acting as an International Preliminary Examining Authority is normally not to carry out a preliminary examination on matter which has not been searched. This is the case irrespective of whether or not the claims are amended following receipt of the search report or during any Chapter II procedure.

# INTERNATIONAL SEARCH REPORT

Information on patent family members

International Application No

PCT/US 00/33793

Patent document cited in search report	A	Publication date		Patent family member(s)	Publication date
WO 9528497	A	26-10-1995		AU 2290195 A	10-11-1995
				EP 0759090 A	26-02-1997
				US 5702897 A	30-12-1997
WO 9500642	A	05-01-1995		US 5646008 A	08-07-1997
				AU 7177394 A	17-01-1995
				CA 2165969 A	05-01-1995
				EP 0706568 A	17-04-1996
				JP 9502603 T	18-03-1997
				US 5834309 A	10-11-1998
WO 9745128	A	04-12-1997		US 5834234 A	10-11-1998
				EP 0910387 A	28-04-1999
				JP 2000510686 T	22-08-2000
				US 6057132 A	02-05-2000
US 5691179	A	25-11-1997		AU 688368 B	12-03-1998
				AU 7604994 A	21-03-1995
				BR 9407583 A	07-01-1997
				CA 2170143 A	02-03-1995
				EP 0722275 A	24-07-1996
				JP 9502088 T	04-03-1997
				JP 2000336100 A	05-12-2000
				NZ 271929 A	25-03-1998
				WO 9505750 A	02-03-1995
				US 5700638 A	23-12-1997
				US 5856171 A	05-01-1999
				US 5834209 A	10-11-1998
				US 5955595 A	21-09-1999
				US 5942490 A	24-08-1999
	US 6184202 B	06-02-2001			